WO2003080049A1 - (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof - Google Patents

(+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof Download PDF

Info

Publication number
WO2003080049A1
WO2003080049A1 PCT/US2003/008738 US0308738W WO03080049A1 WO 2003080049 A1 WO2003080049 A1 WO 2003080049A1 US 0308738 W US0308738 W US 0308738W WO 03080049 A1 WO03080049 A1 WO 03080049A1
Authority
WO
WIPO (PCT)
Prior art keywords
ethoxy
methoxyphenyl
dione
methylsulfonylethyl
acetylaminoisoindoline
Prior art date
Application number
PCT/US2003/008738
Other languages
French (fr)
Inventor
Peter H. Schafer
George W. Muller
Hon-Wah Man
Chuansheng Ge
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28457137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003080049(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DK03721414T priority Critical patent/DK1485087T3/en
Priority to NZ535798A priority patent/NZ535798A/en
Priority to KR1020137021411A priority patent/KR20130100219A/en
Priority to EP10162667.9A priority patent/EP2223688B1/en
Priority to SI200331659T priority patent/SI1485087T1/en
Priority to AT03721414T priority patent/ATE440599T1/en
Priority to DE60328974T priority patent/DE60328974D1/en
Priority to EP15177140.9A priority patent/EP2962690B1/en
Priority to AU2003224729A priority patent/AU2003224729C9/en
Priority to EP19151685.5A priority patent/EP3524242A1/en
Priority to EP03721414A priority patent/EP1485087B1/en
Application filed by Celgene Corporation filed Critical Celgene Corporation
Priority to KR1020107003988A priority patent/KR101104991B1/en
Priority to KR1020047015190A priority patent/KR100997001B1/en
Priority to JP2003577877A priority patent/JP2005525386A/en
Priority to IL16414703A priority patent/IL164147A0/en
Priority to KR1020137004997A priority patent/KR101383845B1/en
Priority to MXPA04009075A priority patent/MXPA04009075A/en
Priority to CA2479666A priority patent/CA2479666C/en
Priority to MX2015010082A priority patent/MX366328B/en
Priority to KR1020127000230A priority patent/KR101263786B1/en
Publication of WO2003080049A1 publication Critical patent/WO2003080049A1/en
Priority to IL164147A priority patent/IL164147A/en
Priority to HK05104139.9A priority patent/HK1073426A1/en
Priority to IL207149A priority patent/IL207149A/en
Priority to CY20191100372T priority patent/CY1121720T1/en
Priority to LU00125C priority patent/LUC00125I2/fr
Priority to BE2019C008C priority patent/BE2019C008I2/nl
Priority to CY2019032C priority patent/CY2019032I2/en
Priority to NL300994C priority patent/NL300994I2/en
Priority to FR19C1046C priority patent/FR19C1046I2/en
Priority to CY20191100877T priority patent/CY1121888T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to methods of using and compositions comprising the (+) enantiomer of 2-[ 1 -(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline- 1 ,3-dione.
  • Tumor necrosis factor alpha (TNF- ⁇ ) is a cytokine that is released primarily by mononuclear phagocytes in response to immunostimulators. TNF- ⁇ is capable of enhancing most cellular processes, such as differentiation, recruitment, proliferation, and proteolytic degradation. At low levels, TNF- ⁇ confers protection against infective agents, tumors, and tissue damage. But TNF- ⁇ also has a role in many diseases. When administered to mammals or humans, TNF- ⁇ causes or aggravates inflammation, fever, cardiovascular effects, hemonhage, coagulation, and acute phase responses similar to those seen during acute infections and shock states.
  • Enhanced or unregulated TNF- ⁇ production has been implicated in a number of diseases and medical conditions, for example, cancers, such as solid tumors and blood-born tumors; heart disease, such as congestive heart failure; and viral, genetic, inflammatory, allergic, and autoimmune diseases.
  • Adenosine 3 ',5 '-cyclic monophosphate also plays a role in many diseases and conditions, such as but not limited to asthma and inflammation, and other conditions (Lowe and Cheng, Drugs of the Future, 17(9), 799-807, 1992). It has been shown that the elevation of cAMP in inflammatory leukocytes inhibits their activation and the subsequent release of inflammatory mediators, including TNF- ⁇ and NF- ⁇ B. Increased levels of cAMP also leads to the relaxation of airway smooth muscle.
  • PDE cyclic nucleotide phosphodiesterases
  • PDE 4 PDE IV
  • compounds that inhibit PDE4 may inhibit inflammation and aid the relaxation of airway smooth muscle with a minimum of unwanted side effects, such as cardiovascular or anti-platelet effects.
  • PDE4 inhibitors lack the selective action at acceptable therapeutic doses.
  • Cancer is a particularly devastating disease, and increases in blood TNF- ⁇ levels are implicated in the risk of and the spreading of cancer.
  • cancer cells Normally, in healthy subjects, cancer cells fail to survive in the circulatory system, one of the reasons being that the lining of blood vessels acts as a barrier to tumor-cell extravasation.
  • increased levels of cytokines have been shown to substantially increase the adhesion of cancer cells to endothelium in vitro.
  • cytokines such as TNF- ⁇ , stimulate the biosynthesis and expression of a cell surface receptors called ELAM-1 (endothelial leukocyte adhesion molecule).
  • ELAM-1 is a member of a family of calcium-dependent cell adhesion receptors, known as LEC-CAMs, which includes LECAM-1 and GMP-140. During an inflammatory response, ELAM-1 on endothelial cells functions as a "homing receptor" for leukocytes. Recently, ELAM-1 on endothelial cells was shown to mediate the increased adhesion of colon cancer cells to endothelium treated with cytokines (Rice et al. , 1989, Science 246:1303-1306).
  • Inflammatory diseases such as arthritis, related arthritic conditions (e.g., osteoarthritis and rheumatoid arthritis), inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis), sepsis, psoriasis, atopic dermatitis, contact dermatitis, and chronic obstructive pulmonary disease, chronic inflammatory pulmonary diseases are also prevalent and problematic ailments.
  • TNF- ⁇ plays a central role in the inflammatory response and the administration of their antagonists block chronic and acute responses in animal models of inflammatory disease.
  • Enhanced or unregulated TNF- ⁇ production has been implicated in viral, genetic, inflammatory, allergic, and autoimmune diseases.
  • diseases include but are not limited to: HIV; hepatitis; adult respiratory distress syndrome; bone-resorption diseases; chronic obstructive pulmonary diseases; chronic pulmonary inflammatory diseases; asthma, dermatitis; cystic fibrosis; septic shock; sepsis; endotoxic shock; hemodynamic shock; sepsis syndrome; post ischemic reperfusion injury; meningitis; psoriasis; fibrotic disease; cachexia; graft rejection; auto-immune disease; rheumatoid spondylitis; arthritic conditions, such as rheumatoid arthritis and osteoarthritis; osteoporosis; Crohn's disease; ulcerative colitis; inflammatory-bowel disease; multiple sclerosis; systemic lupus erythrematosus; ENL in leprosy; radiation damage; asthma; and hyperoxic al
  • T ⁇ F- ⁇ Pharmaceutical compounds that can block the activity or inhibit the production of certain cytokines, including T ⁇ F- ⁇ , may be beneficial therapeutics.
  • Many small-molecule inhibitors have demonstrated an ability to treat or prevent inflammatory diseases implicated by T ⁇ F- ⁇ (for a review, see Lowe, 1998 Exp. Opin. Ther. Patents 8:1309-1332).
  • One such class of molecules are the substituted phenethylsulfones described in United States patent number 6,020,358.
  • This invention relates to methods of treating diseases and disorders utilizing an enantiomer of a substituted phenethylsulfone compound and pharmaceutically acceptable salts, hydrates, solvates, clathrates, prodrugs and polymorphs thereof and methods for reducing the level of cytokines and their precursors in mammals.
  • the invention also relates to pharmaceutical compositions comprising an enantiomer of 2-[l-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline- 1 ,3-dione and a pharmaceutically acceptable carrier.
  • the invention further relates to an enantiomer of 2-[l- (3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione substantially free of its other enantiomer.
  • This invention particularly relates to the (+) enantiomer of 2-[l-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl] -4-acetylaminoisoindoline- 1 ,3 -dione.
  • This compound is believed to have increased potency and other benefits as compared to its racemate — 2-[l-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline-l,3-dione.
  • the invention encompasses the use of the (+) enantiomer of 2-[l-(3-Ethoxy- 4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione for treating or preventing diseases or disorders ameliorated by the inhibition of TNF- ⁇ production in mammals.
  • this treatment includes the reduction or avoidance of adverse effects.
  • Such disorders include, but are not limited to, cancers, including, but not limited to cancer of the head, thyroid, neck, eye, skin, mouth, throat, esophagus, chest, bone, blood, bone manow, lung, colon, sigmoid, rectum, stomach, prostate, breast, ovaries, kidney, liver, pancreas, brain, intestine, heart, adrenal, subcutaneous tissue, lymph nodes, heart, and combinations thereof.
  • cancers including, but not limited to cancer of the head, thyroid, neck, eye, skin, mouth, throat, esophagus, chest, bone, blood, bone manow, lung, colon, sigmoid, rectum, stomach, prostate, breast, ovaries, kidney, liver, pancreas, brain, intestine, heart, adrenal, subcutaneous tissue, lymph nodes, heart, and combinations thereof.
  • Specific cancers that can be treated by this method are multiple myeloma, malignant melanoma, malignant glioma, leukemia and solid tumors.
  • the invention also encompasses the use of the (+) enantiomer of 2-[l-(3- Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione in the treatment or prevention of heart disease, including, but not limited to congestive heart failure, cardiomyopathy, pulmonary edema, endotoxin-mediated septic shock, acute viral myocarditis, cardiac allograft rejection, and myocardial infarction.
  • the invention also encompasses the use of the (+) enantiomer of 2-[l-(3- Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline- 1 ,3-dione to treat diseases or disorders ameliorated by the inhibition of PDE4.
  • the compounds and compositions of the invention maybe useful to treat or prevent viral, genetic, inflammatory, allergic, and autoimmune diseases.
  • diseases include, but are not limited to: HIV; hepatitis; adult respiratory distress syndrome; bone-resorption diseases; chronic obstructive pulmonary diseases; chronic pulmonary inflammatory diseases; dermatitis; inflammatory skin disease, atopic dermatitis, cystic fibrosis; septic shock; sepsis; endotoxic shock; hemodynamic shock; sepsis syndrome; post ischemic reperfusion injury; meningitis; psoriasis; fibrotic disease; cachexia; graft rejection including graft versus host disease; auto-immune disease; rheumatoid spondylitis; arthritic conditions, such as rheumatoid arthritis and osteoarthritis; osteoporosis; Crohn's disease; ulcerative colitis; inflammatory-bowel disease; multiple sclerosis; systemic lupus erythrematosus; erythema nodosum leprosum (ENL) in leprosy; radiation damage; asthma;
  • the stereomerically pure (+) enantiomer of 2-[l- (3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione is also useful in the treatment or prevention of microbial infections or the symptoms of microbial infections including, but not limited to, bacterial infections, fungal infections, malaria, mycobacterial infection, and opportunistic infections resulting from HIV.
  • the invention further encompasses pharmaceutical compositions and single unit dosage forms comprising an enantiomer of 2-[l-(3-Ethoxy-4-methoxyphenyl)-2- methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione and pharmaceutically acceptable polymorphs, prodrugs, salts, hydrates, clathrates, and solvates thereof.
  • the invention encompasses the (+) enantiomer of
  • the invention encompasses a method of producing a stereomerically pure enantiomer of 2-[l-(3-Ethoxy-4-methoxyphenyl)-2- methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione which comprises contacting l-(3-Ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethylamine with a chiral amino acid and contacting the product of the first step with
  • the invention encompasses a chiral salt of 1 -(3-Ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethylamine.
  • FIG 1. illustrates the preparation of the (+) enantiomer of 2-[l-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione.
  • FIG 2. illustrates the effect of the enantiomer of the invention on LPS- induced neutrophilia in the lungs of conscious fenets.
  • Compound A refers to an enantiomerically pure form of2-[l-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3- dione which comes off of an HPLC column at about 25.4 minutes when that column is a 150 mm x 4.6 mm Ultron Chiral ES-OVS chiral HPLC column (Agilent Technology), the eluent is 15:85 ethanol: 20 mM KH 2 PO at pH 3.5, and the observation wavelength is 240 nm.
  • Compound A is believed to be S- ⁇ 2-[l-(3- ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione ⁇ , which has the following structure:
  • the term "patient” refers to a mammal, particularly a human.
  • pharmaceutically acceptable salts refer to salts prepared from pharmaceutically acceptable non- toxic acids or bases including inorganic acids and bases and organic acids and bases.
  • Suitable pharmaceutically acceptable base addition salts for the compound of the present invention include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, N,N'-dibenzylethylenediamine, chloroprocaine, cholme, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.
  • Suitable non-toxic acids include, but are not limited to, inorganic and organic acids such as acetic, alginic, anthranilic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, formic, fumaric, furoic, galacturonic, gluconic, glucuronic, glutamic, glycolic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phenylacetic, phosphoric, propionic, salicylic, stearic, succinic, sulfanilic, sulfuric, tartaric acid, and p-toluenesulfonic acid.
  • inorganic and organic acids such as acetic, alginic, anthranilic, benzenesulfonic, benzoic, camphorsulfonic
  • prodrug means a derivative of a compound that can hydrolyze, oxidize, or otherwise react under biological conditions (in vitro or in vivo) to provide the compound.
  • prodrugs include, but are not limited to, derivatives and metabolites of Compound A that include biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues.
  • biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues.
  • Prodrugs can typically be prepared using well-known methods, such as those described by 1 Burger's Medicinal Chemistry and Drug Discovery, 172-178, 949-982 (Manfred E. Wolff erf., 5th ed. 1995).
  • biohydrolyzable amide means an amide, ester, carbamate, carbonate, ureide, or phosphate, respectively, of a compound that either: 1) does not interfere with the biological activity of the compound but can confer upon that compound advantageous properties in vivo, such as uptake, duration of action, or onset of action; or 2) is biologically inactive but is converted in vivo to the biologically active compound.
  • biohydrolyzable esters include, but are not limited to, lower alkyl esters, alkoxyacyloxy esters, alkyl acylamino alkyl esters, and choline esters.
  • biohydrolyzable amides include, but are not limited to, lower alkyl amides, ⁇ -amino acid amides, alkoxyacyl amides, and alkylaminoalkylcarbonyl amides.
  • biohydrolyzable carbamates include, but are not limited to, lower alkylamines, substituted ethylenediamines, aminoacids, hydroxyalkylamines, heterocyclic and heteroaromatic amines, and polyether amines.
  • stereomerically pure means a composition that comprises one stereoisomer of a compound and is substantially free of other stereoisomers of that compound.
  • a stereomerically pure composition of a compound having one chiral center will be substantially free of the opposite enantiomer of the compound.
  • a stereomerically pure composition of a compound having two chiral centers will be substantially free of other diastereomers of the compound.
  • a typical stereomerically pure compound comprises greater than about 80% by weight of one stereoisomer of the compound and less than about 20% by weight of other stereoisomers of the compound, more preferably greater than about 90% by weight of one stereoisomer of the compound and less than about 10% by weight of the other stereoisomers of the compound, even more preferably greater than about 95% by weight of one stereoisomer of the compound and less than about 5% by weight of the other stereoisomers of the compound, and most preferably greater than about 97% by weight of one stereoisomer of the compound and less than about 3% by weight of the other stereoisomers of the compound.
  • the term “enantiomerically pure” means a stereomerically pure composition of a compound having one chiral center.
  • adverse effects includes, but is not limited to gastrointestinal, renal and hepatic toxicities, leukopenia, increases in bleeding times due to, e.g., thrombocytopenia, and prolongation of gestation, nausea, vomiting, somnolence, asthenia, dizziness, teratogenicity, extra-pyramidal symptoms, akathisia, cardiotoxicity including cardiovascular disturbances, inflammation, male sexual dysfunction, and elevated serum liver enzyme levels.
  • gastrointestinal toxicities includes but is not limited to gastric and intestinal ulcerations and erosions.
  • renal toxicities includes but is not limited to such conditions as papillary necrosis and chronic interstitial nephritis.
  • This invention relates to stereomerically pure Compound A, which is an enantiomer of 2-[ 1 -(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline-l,3-dione, substantially free of its other enantiomer, as well as novel methods using, and compositions comprising stereomerically pure Compound A.
  • the present invention encompasses the in vitro and in vivo use of Compound A, and the incorporation of Compound A into pharmaceutical compositions and single unit dosage forms useful in the treatment and prevention of a variety of diseases and disorders.
  • TNF- ⁇ or inhibition of PDE4 Diseases and disorders which are ameliorated by the reduction of levels of TNF- ⁇ or inhibition of PDE4 are well known in the art and are described herein. Specific methods of the invention reduce or avoid the adverse effects associated with compounds used as TNF- ⁇ inhibitor. Other specific methods of the invention reduce or avoid the adverse effects associated with use of racemic 2-[l-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline-l,3-dione. Specific methods of the invention include methods of treating or preventing diseases and disorders including, but not limited to, solid tumor cancers, blood-born cancers and inflammatory diseases.
  • compositions of the invention which comprise Compound A or a pharmaceutically acceptable polymorph, prodrug, salt, clathrate, solvate or hydrate thereof, can be used in the methods of the invention.
  • a first embodiment of the invention relates to a method of inhibiting TNF- ⁇ production which comprises contacting a cell exhibiting abnormal TNF- ⁇ production with an effective amount of stereomerically pure Compound A, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
  • the invention relates to a method of inhibiting TNF- ⁇ production which comprises contacting a mammalian cell exhibiting abnormal TNF- ⁇ production with an effective amount of stereomerically pure Compound A, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
  • the invention also relates to a method of treating or preventing disorders ameliorated by the reduction of levels of TNF- ⁇ in a patient which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of stereomerically pure compound A, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
  • a further embodiment of the invention relates to a method of treating or preventing cancer, including but not limited to, solid tumor, blood-born tumor, leukemias, and in particular, multiple myeloma in a patient which comprises administering to a patient in need of such treatment or prevention a therapeutically effective amount of stereomerically pure compound A, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof; in particular wherein the patient is a mammal.
  • the invention in another embodiment, relates to a method of inhibiting PDE4 which comprises contacting PDE4 with an effective amount of stereomerically pure Compound A, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
  • the invention in another embodiment, relates to a method of controlling cAMP levels in a cell which comprises contacting a cell with an effective amount of stereomerically pure Compound A, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
  • controlling cAMP levels includes preventing or reducing the rate of the breakdown of Adenosine 3',5'-cyclic monophosphate (cAMP) in a cell or increasing the amount of Adenosine 3',5'-cyclic monophosphate present in a cell, preferably a mammalian cell, more preferably a human cell, hi a particular method, the rate of cAMP breakdown is reduced by about 10, 25, 50, 100, 200, or 500 percent as compared to the rate in comparable cells which have not been contacted with a compound of the invention.
  • cAMP Adenosine 3',5'-cyclic monophosphate
  • a further embodiment of the invention relates to a method of treating or preventing diseases or disorders ameliorated by the inhibition of PDE4 in a patient which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of stereomerically pure Compound A, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
  • Disorders ameliorated by the inhibition of PDE4 include, but are not limited to, asthma, inflammation (e.g., inflammation due to reperfusion), chronic or acute obstructive pulmonary diseases, chronic or acute pulmonary inflammatory diseases, inflammatory bowel disease, Crohn's Disease, Bechet's Disease, or colitis.
  • a further embodiment of the invention relates to a method of treating or preventing depression, asthma, inflammation (e.g., contact dermatitis, atopic dermatitis, psoriais, rheumatoid arthritis, osteoarthritis, inflammatory skin disease, inflammation due to reperfusion), chronic or acute obstructive pulmonary diseases, chronic or pulmonary inflammatory diseases, inflammatory bowel disease, Crohn's Disease, Bechet's Disease or colitis in a patient which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of stereomerically pure Compound A, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof; in particular wherein the patient is a mammal.
  • inflammation e.g., contact dermatitis, atopic dermatitis, psoriais, rheumatoid arthritis, osteoarthritis, inflammatory skin disease, inflammation
  • a separate embodiment of the invention encompasses methods of treating or preventing Myelodysplastic syndrome (MDS) which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of stereomerically pure Compound A, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.
  • MDS refers to a diverse group of hematopoietic stem cell disorders. MDS is characterized by a cellular marrow with impaired morphology and maturation (dysmyelopoiesis), peripheral blood cytopenias, and a variable risk of progression to acute leukemia, resulting from ineffective blood cell production. See The Merck Manual 953 (17th ed.
  • a separate embodiment of the invention encompasses methods of treating or preventing Myeloprohferative disease (MPD) which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of stereomerically pure Compound A, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clatlirate, or prodrug thereof.
  • MPD Myeloprohferative disease refers to a group of disorders characterized by clonal abnormalities of the hematopoietic stem cell. See e.g., Current Medical Diagnosis & Treatment, pp. 499 (37th ed., Tierney et al. ed, Appleton & Lange, 1998).
  • the invention also encompasses a method of treating, preventing or managing complex regional pain syndrome, which comprises administering to a patient in need of such treatment, prevention or management a therapeutically or prophylactically effective amount of a stereomerically pure Compound A, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, hi a specific embodiment, the administration is before, during or after surgery or physical therapy directed at reducing or avoiding a symptom of complex regional pain syndrome in the patient.
  • stereomerically pure Compound A, or a pharmaceutically acceptable polymorph, prodrug, salt, solvate, hydrate, or clathrate thereof is adjunctively administered with at least one additional therapeutic agent.
  • additional therapeutic agents include, but are not limited to, anti-cancer drugs, anti-inflammatories, antihistamines and decongestants.
  • Racemic 2- [ 1 -(3 -Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl] -4- acetylaminoisoindoline-l,3-dione is readily prepared using the methods in United States Patent No. 6,020,358, which is incorporated herein by reference.
  • Compound A can be isolated from the racemic compound by techniques known in the art. Examples include, but are not limited to, the formation of chiral salts and the use of chiral or high performance liquid chromatography "HPLC" and the formation and crystallization of chiral salts. See, e.g., Jacques, J., et al, Enantiomers, Racemates and Resolutions (Wiley-Interscience, New York, 1981); Wilen, S. H., et al, Tetrahedron
  • Compound A is synthesized from 3-acetamidophthalic anhydride and a chiral amino acid salt of (S)-2-(3-ethoxy-4-methoxyphenyl)-l- (methylsulphonyl)-eth-2-ylamine.
  • (S)-2-(3-ethoxy-4-methoxyphenyl)-l-(methylsulphonyl)-eth-2-ylamine include, but not limited to salts formed with the L isomers of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosme, valine, ornithine, 4-aminobutyric acid, 2 amino isobutyric acid, 3 amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, and
  • a specific chiral amino acid salt is (S)-2-(3-ethoxy-4-methoxyphenyl)- 1 -(methylsulphonyl)-eth-2-ylamine N-acetyl-L-leucine salt, which is resolved from 2-(3-ethoxy-4-methoxyphenyl)-l-(methylsulphonyl)-eth-2- ylamine and N-acetyl-L-leucine in methanol.
  • the invention encompasses methods of treating and preventing diseases or disorders ameliorated by the reduction of levels of TNF- ⁇ in a patient which comprise administering to a patient in need of such treatment or prevention a therapeutically effective amount of stereomerically pure Compound A, or a phannaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
  • disorders ameliorated by the inhibition of TNF- ⁇ include, but are not limited to: heart disease, such as congestive heart failure, cardiomyopathy, pulmonary edema, endotoxin-mediated septic shock, acute viral myocarditis, cardiac allograft rejection, and myocardial infarction; solid tumors, including but not limited to, sarcoma, carcinomas, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothehoma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcino
  • Specific methods of the invention further comprise the administration of an additional therapeutic agent (i.e., a therapeutic agent other than Compound A).
  • additional therapeutic agents include, but are not limited to, anti-cancer drugs such as, but are not limited to: alkylating agents, nitrogen mustards, ethylenimines, methylmelamines, alkyl sulfonates, nitrosoureas, triazenes, folic acid analofs, pyrimidine analogs, purine analogs, vinca alkaloids, epipodophyllotoxins, antibiotics, topoisomerase inhibitors and anti-cancer vaccines.
  • anti-cancer drugs such as, but are not limited to: alkylating agents, nitrogen mustards, ethylenimines, methylmelamines, alkyl sulfonates, nitrosoureas, triazenes, folic acid analofs, pyrimidine analogs, purine analogs, vinca alkaloids, epipodophyll
  • Specific additional therapeutic agents include, but are not limited to: acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; alfretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil;
  • anti-cancer drugs include, but are not limited to: 20-epi-l,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein- 1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PT
  • B betulinic acid; bFGF inhibitor; bicalutamide; bisanfrene; bisaziridinylspermine; bisnafide; bisfratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorlns; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin
  • the invention further encompasses a method of treating or preventing diseases or disorders ameliorated by the inhibition of PDE4 in a patient which comprise administering to a patient in need of such treatment or prevention a therapeutically effective amount of stereomerically pure Compound A, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
  • Disorders ameliorated by the inhibition of PDE4 include, but are not limited to, asthma, inflammation, chronic or acute obstructive pulmonary disease, chronic or acute pulmonary inflammatory disease, inflammatory bowel disease, Crohn's Disease, Bechet's Disease, colitis, ulcerative colitis and arthritis or inflammation due to reperfusion.
  • the disease or disorder to be treated or prevented is chronic obstructive pulmonary disease.
  • Specific methods of the invention can comprise the administration of an additional therapeutic agent such as, but not limited to, anti-inflammatory drugs, antihistamines and decongestants.
  • additional therapeutic agents include, but are not limited to: antihistamines including, but not limited to, ethanolamines, ethylenediamines, piperazines, and phenothiazines; antinflammatory drugs; NSAIDS, including, but not limited to, aspirin, sahcylates, acetominophen, indomethacin, sulindac, etodolac, fenamates, tolmetin, ketorolac, diclofenac, ibuprofen, naproxen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin, piroxicam, meloxicam, pyrazolon derivatives; and steriods including, but not limited to, cortical steroids and adrenocortical steroids.
  • stereomerically pure Compound A may further provide an overall improved therapeutic effectiveness, or therapeutic index, over racemic 2-[l-(3-Ethoxy-4-methoxyphenyl)-2- methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione.
  • a smaller amount of the drug may in some circumstances be administered to attain the same level of effectiveness.
  • the active compound of the invention may be used in the treatment or prevention of a wide range of diseases and conditions.
  • the magnitude of a prophylactic or therapeutic dose of a particular active ingredient of the invention in the acute or chronic management of a disease or condition will vary, however, with the nature and severity of the disease or condition, and the route by which the active ingredient is administered.
  • the dose, and perhaps the dose frequency will also vary according to the age, body weight, and response of the individual patient.
  • Suitable dosing regimens can be readily selected by those skilled in the art with due consideration of such factors, hi general, the recommended daily dose range for the conditions described herein lie within the range of from about 1 mg to about 1000 mg per day, given as a single once-a- day dose preferably as divided doses throughout a day. More specifically, the daily dose is administered twice daily in equally divided doses. Specifically, a daily dose range should be from about 5 mg to about 500 mg per day, more specifically, between about 10 mg and about 200 mg per day. Specifically, the daily dose may be administered in 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 50 mg, orlOO mg dosage forms.
  • the therapy should be initiated at a lower dose, perhaps about 1 mg to about 25 mg, and increased if necessary up to about 200 mg to about 1000 mg per day as either a single dose or divided doses, depending on the patient's global response.
  • the daily dose is from 0.01 mg/kg to 100 mg/kg.
  • therapeutically effective amount encompasses the above described dosage amounts and dose frequency schedules. Different therapeutically effective amounts may be applicable for different diseases and conditions, as will be readily known by those of ordinary skill in the art. Similarly, amounts sufficient to treat or prevent such disorders, but insufficient to cause, or sufficient to reduce, adverse effects associated with racemic 2-[l-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-l,3-dione are also encompassed by the above described dosage amounts and dose frequency schedules.
  • compositions and single unit dosage forms comprising Compound A, or a pharmaceutically acceptable polymorph, prodrug, salt, solvate, hydrate, or clathrate thereof, are encompassed by the invention.
  • Individual dosage forms of the invention may be suitable for oral, mucosal (including rectal, nasal, or vaginal), parenteral (including subcutaneous, intramuscular, bolus injection, intraarterial, or intravenous), sublingual, transdermal, buccal, or topical administration.
  • compositions and dosage forms of the invention comprise stereomerically pure Compound A, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
  • Pharmaceutical compositions and dosage forms of the invention typically also comprise one or more pharmaceutically acceptable excipients.
  • a particular pharmaceutical composition encompassed by this embodiment comprises stereomerically pure Compound A, or a pharmaceutically acceptable polymorph, prodrug, salt, solvate, hydrate, or clathrate thereof, and at least one additional therapeutic agent.
  • additional therapeutic agents include, but are not limited to: anti-cancer drugs and anti-inflammation therapies including, but not limited to, those listed above in section 4.2.
  • Single unit dosage forms of the invention are suitable for oral, mucosal (e.g., nasal, sublingual, vaginal, buccal, or rectal), parenteral (e.g., subcutaneous, intravenous, bolus injection, intramuscular, or intraarterial), or transdermal administration to a patient.
  • mucosal e.g., nasal, sublingual, vaginal, buccal, or rectal
  • parenteral e.g., subcutaneous, intravenous, bolus injection, intramuscular, or intraarterial
  • transdermal administration to a patient.
  • dosage forms include, but are not limited to: tablets; caplets; capsules, such as soft elastic gelatin capsules; cachets; troches; lozenges; dispersions; suppositories; ointments; cataplasms (poultices); pastes; powders; dressings; creams; plasters; solutions; patches; aerosols (e.g., nasal sprays or inhalers); gels; liquid dosage forms suitable for oral or mucosal administration to a patient, including suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in- water emulsions, or a water-in-oil liquid emulsions), solutions, and elixirs; liquid dosage forms suitable for parenteral administration to a patient; and sterile solids (e.g., crystalline or amorphous solids) that can be reconstituted to provide liquid dosage forms suitable for parenteral administration to a patient.
  • suspensions e.g., aqueous
  • composition, shape, and type of dosage forms of the invention will typically vary depending on their use.
  • a dosage form used in the acute treatment of inflammation or a related disorder may contain larger amounts of one or more of the active ingredients it comprises than a dosage form used in the chronic treatment of the same disease.
  • a parenteral dosage form may contain smaller amounts of one or more of the active ingredients it comprises than an oral dosage form used to treat the same disease or disorder.
  • Typical pharmaceutical compositions and dosage forms comprise one or more excipients.
  • Suitable excipients are well known to those skilled in the art of pharmacy, and non-limiting examples of suitable excipients are provided herein. Whether a particular excipient is suitable for incorporation into a pharmaceutical composition or dosage form depends on a variety of factors well known in the art including, but not limited to, the way in which the dosage form will be administered to a patient.
  • oral dosage forms such as tablets may contain excipients not suited for use in parenteral dosage forms. The suitability of a particular excipient may also depend on the specific active ingredients in the dosage form.
  • Lactose-free compositions of the invention can comprise excipients that are well known in the art and are listed, for example, in the U.S. Pharmocopia (USP) SP (XXI)/NF (XVI).
  • USP U.S. Pharmocopia
  • XXI U.S. Pharmocopia
  • NF NF
  • lactose-free compositions comprise an active ingredient, a binder/filler, and a lubricant in pharmaceutically compatible and pharmaceutically acceptable amounts.
  • Prefened lactose-free dosage forms comprise an active ingredient, microcrystalline cellulose, pre-gelatinized starch, and magnesium stearate.
  • This invention further encompasses anhydrous pharmaceutical compositions and dosage forms comprising active ingredients, since water can facilitate the degradation of some compounds.
  • water e.g., 5%
  • water is widely accepted in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf-life or the stability of formulations over time. See, e.g., Jens T. Carstensen, Drug Stability: Principles & Practice, 2d. Ed., Marcel Dekker, NY, NY, 1995, pp. 379-80.
  • water and heat accelerate the decomposition of some compounds.
  • the effect of water on a formulation can be of great significance since moisture and/or humidity are commonly encountered during manufacture, handling, packaging, storage, shipment, and use of formulations.
  • Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions.
  • Pharmaceutical compositions and dosage forms that comprise lactose and at least one active ingredient that comprises a primary or secondary amine are preferably anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected.
  • anhydrous pharmaceutical composition should be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are preferably packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g., vials), blister packs, and strip packs.
  • compositions and dosage forms that comprise one or more compounds that reduce the rate by which an active ingredient will decompose.
  • stabilizers include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers.
  • the amounts and specific types of active ingredients in a dosage form may differ depending on factors such as, but not limited to, the route by which it is to be administered to patients.
  • typical dosage forms of the invention comprise compound A, or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, polymoprh or prodrug thereof lie within the range of from about 1 mg to about 1000 mg per day, given as a single once-a-day dose in the morning but preferably as divided doses throughout the day taken with food. More specifically, the daily dose is administered twice daily in equally divided doses.
  • a daily dose range should be from about 5 mg to about 500 mg per day, more specifically, between about 10 mg and about 200 mg per day.
  • the therapy should be initiated at a lower dose, perhaps about 1 mg to about 25 mg, and increased if necessary up to about 200 mg to about 1000 mg per day as either a single dose or divided doses, depending on the patient's global response.
  • compositions of the invention that are suitable for oral administration can be presented as discrete dosage forms, such as, but are not limited to, tablets (e.g., chewable tablets), caplets, capsules, and liquids (e.g., flavored syrups).
  • dosage forms contain predetermined amounts of active ingredients, and maybe prepared by methods of pharmacy well known to those skilled in the art. See generally, Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton PA (1990).
  • Typical oral dosage forms of the invention are prepared by combining the active ingredient(s) in an intimate admixture with at least one excipient according to conventional pharmaceutical compounding techniques.
  • Excipients can take a wide variety of fonns depending on the form of preparation desired for administration.
  • excipients suitable for use in oral liquid or aerosol dosage forms include, but are not limited to, water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents.
  • excipients suitable for use in solid oral dosage forms include, but are not limited to, starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents.
  • tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid excipients are employed.
  • tablets can be coated by standard aqueous or nonaqueous techniques.
  • Such dosage forms can be prepared by any of the methods of pharmacy, hi general, pharmaceutical compositions and dosage forms are prepared by uniformly and intimately admixing the active ingredients with liquid carriers, finely divided solid carriers, or both, and then shaping the product into the desired presentation if necessary.
  • a tablet can be prepared by compression or molding.
  • Compressed tablets can be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as powder or granules, optionally mixed with an excipient. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • excipients that can be used in oral dosage forms of the invention include, but are not limited to, binders, fillers, disintegrants, and lubricants.
  • Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, (e.g., Nos. 2208, 2906, 2910), microcrystalline cellulose, and mixtures thereof.
  • natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl
  • fillers suitable for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.
  • the binder or filler in pharmaceutical compositions of the invention is typically present in from about 50 to about 99 weight percent of the pharmaceutical composition or dosage form.
  • Suitable forms of microcrystalline cellulose include, but are not limited to, the materials sold as AVICEL-PH-101, AVICEL-PH-103 ANICEL RC-581, ANICEL-PH-105 (available from FMC Corporation, American Viscose Division, Avicel Sales, Marcus Hook, PA), and mixtures thereof.
  • An specific binder is a mixture of microcrystalline cellulose and sodium carboxymethyl cellulose sold as AVICEL RC-581.
  • Suitable anhydrous or low moisture excipients or additives include AVICEL-PH-103TM and Starch 1500 LM.
  • Disintegrants are used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment. Tablets that contain too much disintegrant may disintegrate in storage, while those that contain too little may not disintegrate at a desired rate or under the desired conditions. Thus, a sufficient amount of disintegrant that is neither too much nor too little to detrimentally alter the release of the active ingredients should be used to form solid oral dosage forms of the invention.
  • the amount of disintegrant used varies based upon the type of formulation, and is readily discernible to those of ordinary skill in the art.
  • Typical pharmaceutical compositions comprise from about 0.5 to about 15 weight percent of disintegrant, specifically from about 1 to about 5 weight percent of disintegrant.
  • Disintegrants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums, and mixtures thereof.
  • Lubricants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, and mixtures thereof.
  • calcium stearate e.g., magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc
  • hydrogenated vegetable oil e.g., peanut oil, cottonseed oil
  • Additional lubricants include, for example, a syloid silica gel (AEROSIL 200, manufactured by W.R. Grace Co. of Baltimore, MD), a coagulated aerosol of synthetic silica (marketed by Degussa Co. of Piano, TX), CAB-O-SIL (a pyrogenic silicon dioxide product sold by Cabot Co. of Boston, MA), and mixtures thereof. If used at all, lubricants are typically used in an amount of less than about 1 weight percent of the pharmaceutical compositions or dosage forms into which they are incorporated.
  • AEROSIL 200 manufactured by W.R. Grace Co. of Baltimore, MD
  • a coagulated aerosol of synthetic silica marketed by Degussa Co. of Piano, TX
  • CAB-O-SIL a pyrogenic silicon dioxide product sold by Cabot Co. of Boston, MA
  • lubricants are typically used in an amount of less than about 1 weight percent of the pharmaceutical compositions or dosage forms into which they are incorporated.
  • Active ingredients of the invention can be administered by controlled release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U.S. Patent Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; and 4,008,719, 5,674,533, 5,059,595, 5,591,767, 5,120,548, 5,073,543, 5,639,476, 5,354,556, and 5,733,566, each of wliich is incorporated herein by reference.
  • Such dosage forms can be used to provide slow or controlled-release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions.
  • Suitable controlled-release formulations known to those of ordinary skill in the art, including those described herein, can be readily selected for use with the active ingredients of the invention.
  • the invention thus encompasses single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled-release.
  • controlled-release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled counterparts.
  • the use of an optimally designed controlled-release preparation in medical treatment is characterized by a minimum of drug substance being employed to cure or control the condition in a minimum amount of time.
  • Advantages of controlled-release formulations include extended activity of the drug, reduced dosage frequency, and increased patient compliance, h addition, controlled-release formulations can be used to affect the time of onset of action or other characteristics, such as blood levels of the drug, and can thus affect the occunence of side (e.g., adverse) effects.
  • Controlled-release formulations are designed to initially release an amount of drug (active ingredient) that promptly produces the desired therapeutic effect, and gradually and continually release of other amounts of drug to maintain this level of therapeutic or prophylactic effect over an extended period of time.
  • the drug In order to maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body.
  • Controlled-release of an active ingredient can be stimulated by various conditions including, but not limited to, pH, temperature, enzymes, water, or other physiological conditions or compounds.
  • Parenteral dosage forms can be administered to patients by various routes including, but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and intraarterial. Because their administration typically bypasses patients' natural defenses against contaminants, parenteral dosage forms are preferably sterile or capable of being sterilized prior to administration to a patient. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions.
  • Suitable vehicles that can be used to provide parenteral dosage forms of the invention are well known to those skilled in the art. Examples include, but are not limited to: Water for hijection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
  • aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection
  • Transdermal, topical, and mucosal dosage forms of the mvention include, but are not limited to, ophthalmic solutions, sprays, aerosols, creams, lotions, ointments, gels, solutions, emulsions, suspensions, or other forms known to one of skill in the art. See, e.g., Remington's Pharmaceutical Sciences, 16th and 18th eds., Mack Publishing, Easton PA (1980 & 1990); and Introduction to Pharmaceutical Dosage Forms, 4th ed., Lea & Febiger, Philadelphia (1985). Dosage forms suitable for treating mucosal tissues within the oral cavity can be formulated as mouthwashes or as oral gels. Further, transdermal dosage forms include "reservoir type" or "matrix type” patches, which can be applied to the skin and worn for a specific period of time to permit the penetration of a desired amount of active ingredients.
  • Suitable excipients e.g. , carriers and diluents
  • other materials that can be used to provide transdermal, topical, and mucosal dosage forms encompassed by this mvention are well known to those skilled in the pharmaceutical arts, and depend on the particular tissue to which a given pharmaceutical composition or dosage form will be applied.
  • excipients include, but are not limited to, water, acetone, ethanol, ethylene glycol, propylene glycol, butane- 1,3-diol, isopropyl myristate, isopropyl palmitate, mineral oil, and mixtures thereof to form lotions, tinctures, creams, emulsions, gels or ointments, which are non-toxic and pharmaceutically acceptable.
  • Moisturizers or humectants can also be added to pharmaceutical compositions and dosage forms if desired.
  • additional ingredients are well known in the art. See, e.g. , Remington 's Pharmaceutical Sciences, 16th and 18th eds., Mack Publishing, Easton PA (1980 & 1990).
  • additional components may be used prior to, in conjunction with, or subsequent to treatment with active ingredients of the invention.
  • penetration enhancers can be used to assist in delivering the active ingredients to the tissue.
  • Suitable penetration enhancers include, but are not limited to: acetone; various alcohols such as ethanol, oleyl, and tetrahydrofuryl; alkyl sulfoxides such as dimethyl sulfoxide; dimethyl acetamide; dimethyl formamide; polyethylene glycol; pynolidones such as polyvinylpynolidone; Kollidon grades (Povidone, Polyvidone); urea; and various water-soluble or insoluble sugar esters such as Tween 80 (polysorbate 80) and Span 60 (sorbitan monostearate).
  • the pH of a pharmaceutical composition or dosage form, or of the tissue to which the pharmaceutical composition or dosage form is applied may also be adjusted to improve delivery of one or more active ingredients.
  • the polarity of a solvent carrier, its ionic strength, or tonicity can be adjusted to improve delivery.
  • Compounds such as stearates can also be added to pharmaceutical compositions or dosage forms to advantageously alter the hydrophilicity or lipophilicity of one or more active ingredients so as to improve delivery.
  • stearates can serve as a lipid vehicle for the formulation, as an emulsifying agent or surfactant, and as a delivery-enhancing or penetration-enhancing agent.
  • Different salts, hydrates or solvates of the active ingredients can be used to further adjust the properties of the resulting composition.
  • active ingredients of the invention are preferably not administered to a patient at the same time or by the same route of administration.
  • This invention therefore encompasses kits which, when used by the medical practitioner, can simplify the administration of appropriate amounts of active ingredients to a patient.
  • a typical kit of the invention comprises a unit dosage form of compound A, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, polymorph or prodrug thereof, and a unit dosage form of a second active ingredient.
  • second active ingredients include, but are not limited to, those listed in section 4.2 above.
  • Kits of the invention can further comprise devices that are used to administer the active ingredient(s).
  • devices include, but are not limited to, syringes, drip bags, patches, and inhalers.
  • Kits of the invention can further comprise pharmaceutically acceptable vehicles that can be used to administer one or more active ingredients.
  • the kit can comprise a sealed container of a suitable vehicle in which the active ingredient can be dissolved to form a particulate-free sterile solution that is suitable for parenteral administration.
  • Examples of pharmaceutically acceptable vehicles include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
  • aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection
  • water-miscible vehicles such as, but not limited to, ethyl alcohol
  • a 3 L 3-necked round bottom flask was equipped with a mechanical stiner, thermometer, and condenser and charged with 2-(3-ethoxy-4-methoxyphenyl)-l - (methylsulphonyl)-eth-2-ylamine (137.0 g, 500 mmol), N-acetyl-L-leucine (52 g, 300 mmol), and methanol (1.0 L).
  • the stfrred slurry was heated to reflux for 1 hour.
  • the stined mixture was allowed to cool to ambient temperature and stirring was continued for another 3 hours at ambient temperature.
  • the slurry was filtered and washed with methanol (250 mL).
  • the solid was air-dried and then dried in vacuo at ambient temperature to a constant weight, giving 109.5 g (98% yield) of the crude product (85.8% ee).
  • the crude solid (55.0 g) and methanol (440 mL) were brought to reflux for 1 hour, cooled to room temperature and stined for an additional 3 hours at ambient temperature.
  • the slurry was filtered and the filter cake was washed with methanol (200 mL).
  • Lipopolysaccharide is an endotoxin produced by gram-negative bacteria such as E. coli which induces production of many pro-inflammatory cytokines, including TNF- ⁇ .
  • PBMC peripheral blood mononuclear cells
  • the TNF- ⁇ produced in response to LPS is derived from monocytes, which comprise approximately 5-20% of the total PBMC.
  • Compounds were tested for the ability to inhibit LPS-induced TNF- ⁇ production from human PBMC as previously described (Muller et al. 1996, J. Med Chem. 39:3238).
  • PBMC from normal donors were obtained by Ficoll Hypaque (Pharmacia, Piscataway, NJ, USA) density centrifugation. Cells were cultured in RPMI (Life Technologies, Grand Island, NY, USA) supplemented with 10% AB ⁇ human serum
  • PBMC peripheral blood mononuclear cells
  • TNF- ⁇ production is often stimulated by the cytokine IL-1 ⁇ , rather than by bacterially derived LPS.
  • Compounds were tested for the ability to inhibit IL-1 ⁇ -induced TNF- ⁇ production from human PBMC as described above for LPS-induced TNF- ⁇ production, except that the PBMC were isolated from source leukocyte units (Sera-Tec Biologicals, North Brunswick, NJ, USA) by centrifugation on Ficoll-Paque Plus (Amersham Pharmacia, Piscataway, NJ, USA), plated in 96-well tissue culture plates at 3 x 10 5 cells/well in RPMI-1640 medium (BioWhittaker, Walkersville, Maryland, USA) containing 10% heat-inactivated fetal bovine serum (Hyclone), 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (complete medium), pretreated with compounds at 10, 2, 0.4, 0.08, 0.016, 0.0032
  • PDE7 is a cAMP-selective PDE expressed mainly in T cells and in skeletal muscle.
  • T cell-derived cytokines such as IL-2 and IFN- ⁇ are potentially regulatable via PDE7 inhibition.
  • PDE7 was purified from Hut78 human T cells by anion exchange chromatography as previously described (Bloom and Beavo 1996, Proc. Natl. Acad Sci. USA 93:14188-14192). Compounds were tested against the PDE7 preparation in the presence of 10 nM cAMP as described for PDE4 in Table 1 below.
  • PDE4 enzyme was purified from U937 human monocytic cells by gel filtration chromatography as previously described (MuUer et al. 1998, Bioorg. & Med Chem Lett 8:2669-2674). Phosphodiesterase reactions were carried out in 50 mM Tris HCl pH 7.5, 5 mM MgCl 2 , 1 ⁇ M cAMP, 10 nM [ 3 H]-cAMP for 30 min at 30°C, terminated by boiling, treated with 1 mg/ml snake venom, and separated using AG-1XS ion exchange resin (BioRad) as described (Muller et al. 1998, Bioorg. &Med Chem Lett 8:2669-267 '4). Reactions consumed less than 15% of available substrate. Results are listed in Table 1.
  • Staphylococcal ⁇ nterotoxin B is a superantigen derived from gram- positive bacteria Staphylococcus aureus. S ⁇ B provides a convenient physiological stimulus specific for T cells expressing particular T cell receptor V ⁇ chains.
  • Human PBMC (consisting of approximately 50% T cells) were isolated from source leukocyte units as described above and plated in 96-well tissue culture plates at 3 x 10 5 cells/well in complete medium, prefreated with compounds at 10, 2, 0.4, 0.08, 0.016, 0.0032, 0.00064, and 0 ⁇ M in duplicate at a final DMSO concentration of 0.1 % at 37°C in a humidified incubator at 5% CO 2 for 1 hour, then stimulated with 100 ng/ml S ⁇ B (Sigma Chemical Co., St. Louis, MO, USA) for 18 hours.
  • IL-2 and IFN- ⁇ levels were measured by ELISA (R&D Systems, Minneapolis, MN, USA).
  • IL-2 IC 50 291 nM.
  • IFN- ⁇ IC 50 46 nM.
  • Prostaglandin E 2 (PGE 2 ) binds to prostanoid receptors on monocytes, T cells and other leukocytes and consequently elevates intracellular cAMP levels, resulting in inhibition of cellular responses.
  • Intracellular cAMP was measured in human PBMC as follows. PBMC were isolated as described above and plated in 96-well plates at 1 x 10 6 cells per well in RPMI-1640.
  • the cells were pre-treated with compounds at 100, 10, 1, 0.1, 0.01, and 0 ⁇ M in a final concentration of 2% DMSO in duplicate at 37°C in a humidified incubator at 5% CO 2 for one hour.
  • the cells were then stimulated with PGE 2 (1 O ⁇ M) (Sigma) for lh.
  • the cells were lysed with HCl, 0.1N final concentration to inhibit phosphodiesterase activity and the plates were frozen at -20°C.
  • the cAMP produced was measured using cAMP (low pH) hnmunoassay kit (R&D Systems).
  • PBMC cAMP EC 50 for racemate is 3.09 ⁇ M.
  • PBMC cAMP EC 50 for Compound A is 1.58 ⁇ M.
  • Elevation of cAMP in human monocytes was measured as follows. PBMC were removed from source leukocytes (Sera-Tec Biologicals) by centrifugation on Ficoll— Paque Plus (Amersham Pharmacia). The resulting erythrocyte/polymorphonuclear cell (PMN) pellet was resuspended in Hank's Balanced Salt Solution (BioWhittaker) and mixed with an equal volume of 3% Dextran T-500 (Amersham Pharmacia) in 0.9% saline. Erythrocytes were allowed to sediment for 20 minutes, and the PMN were removed and centrifuged at 120 rpm for 8 minutes at 4°C.
  • PMN erythrocyte/polymorphonuclear cell
  • N-formyl-methionine-leucine-phenylalanine is a bacterially derived peptide that activates damrophils to rapidly degranulate, migrate, adhere to endothelial cells, and release leukotriene LTB4, a product of arachidonic acid metabolism and itself a damrophil chemoatfractant.
  • LTB4 leukotriene LTB4
  • Neufrophils were isolated as described above and resuspended in phosphate-buffered saline without calcium or magnesium (BioWhittaker) containing 10 mM HEPES pH7.2 and plated in 96-well tissue culture plates at a concenfration of 1.7 x 10 6 cells/well.
  • Cells were treated with 50 ⁇ M thimerosal (SigmaVl mM CaCl 2 /l mM MgCl 2 for 15 minutes at 37°C 5% CO 2 , then treated with compounds at 1000, 200, 40, 8, 1.6, 0.32, 0.064, and 0 nM in a final DMSO concentration of 0.01% in duplicate for 10 minutes.
  • Zymosan-induced IL-8 production Zymosan A or the heat-killed yeast Saccharomyces cerevisiae, binds to the adhesion molecule Mac-1 on the devisrophil surface and triggers phagocytosis, cell activation and IL-8 production.
  • Zymosan-induced IL-8 production was measured as previously described (Au et al. 1998, Brit. J. Pharm. 123:1260-1266) with the following modifications.
  • Human embarkophils were purified as described above, plated in 96-well tissue culture plates at 3xl0 5 cells/well in complete medium, treated with compounds at 10, 2, 0.4, 0.08, 0.016, 0.0032, 0.00064, and 0 ⁇ M in duplicate in a final DMSO concentration of 0.1% for 1 hour at 37°C 5%CO 2 .
  • Neufrophils were then stimulated with unopsonized, boiled Zymosan A (Sigma) at 2.5 x 10 5 particles/well for 18 hours.
  • Supernatants were harvested and tested for IL-8 by ELISA (R&D Systems). Results are shown in Table 2.
  • CD18/CD1 lb (Mac-1) expression on embarkophils was measured as previously described (Derian et al. 1995, J. Immunol: 154:308-3 17) with the following modifications.
  • Neufrophils were isolated as described above, then resuspended in complete medium at lxlO 6 cells/ml, pretreated with compounds at 10, 1, 0.1, 0.01, and 0 ⁇ M in duplicate at a final DMSO concentration of 0.1% for 10 minutes at 37°C 5%CO 2 . Cells were then stimulated with 30 nM fMLF for 30 minutes and then chilled to 4°C.
  • HUVEC Human umbilical vein endothelial cells
  • EXAMPLE 8 LPS-INDUCED LUNG NEUTROPHILIA FERRET MODEL
  • the conscious fenet model has been used to investigate anti-inflammatory, emetic and behavioral effects of PDE4 inhibitors when administered by the oral (p.o.) route. From these experiments, a therapeutic index (TI) for each PDE4 inhibitor may be determined. The TI has been calculated by dividing the threshold dose for causing emetic episodes and behavioral changes by the anti-inflammatory dose (dose that causes 50% inhibition of the LPS-induced neutrophilia).
  • Fercets Male fenets (Mustela Pulorius Euro, weighing 1 - 2 kg). Fercets were supplied either by Bury Green Farm or Misay Consultancy. Following transport, the animals were allowed to acclimatize in the holding rooms for a period of not less than 7 days.
  • the Diet comprised SDS diet C pelleted food given ad lib with Whiskers cat food given 3 times per week. Water was pasteurized animal grade drinking water and was changed daily.
  • PDE4 inhibitors were administered orally (p.o.), at doses initially of 1-10 mg/kg, but subsequently up to 30 mg/kg in order to establish whether the TI was 10 or higher, and/or at lower doses to establish the minimum dose to cause 50% inhibition of neutrophilia.
  • Ferrets were fasted overnight but allowed free access to water.
  • the animals were orally dosed with vehicle or PDE4 inhibitor using a 15cm dosing needle that was passed down the back of the throat into the oesophagus. After dosing, the animals were returned to holding cages fitted with Perspex doors to allow observation, and given free access to water. After dosing, the animals were constantly observed and any emesis or behavioural changes were recorded. The animals were allowed access to food 60 - 90 minutes after p.o. dosing Exposure to LPS
  • a terminal blood sample (10 ml) was removed by trans-thoracic cardiac puncture.
  • the blood was spun at 2500rpm for 15 minutes and the plasma removed and stored at -20°C.
  • the brain also removed and frozen at -20°C for analysis of compound content.
  • the bronchoalveolar lavage (BAL) samples were centrifuged at 1500 rpm for 5 minutes. The supernatant was removed and the resulting cell pellet re-suspended in 1 ml PBS. A cell smear of the re-suspended fluid was prepared and stained with Leishmans stain to allow differential cell counting. A total cell count was made using the remaining resuspended sample. From this, the total number of monrophils in the BAL was determined.
  • Emetic episodes the number of vomits and retches were counted.
  • Behavioral changes - the following behavioral effects were noted: salivation, panting, mouth clawing, flattened posture, ataxia, arched back and backward walking. Any behavioral changes were semi-quantified by applying a severity rating (mild, moderate or severe). 4. The TI was calculated as the highest dose found to not cause emetic episodes divided by the lowest dose found to inhibit pulmonary neutrophilia by 50% or more.
  • the ferrets were observed for at least 2 hours and emetic episodes (vomits and retches) and behavioral changes were recorded. No emetic episodes (retching or vomiting) were observed in the fenets pre- treated p.o. with the relevant vehicle (acetone/cremophor /distilled water), hi a small proportion of the control-treated animals (7/22), mild behavioral changes (lip licking and backward walking) were seen.
  • Compound A (0.1 -3 mg/kg, p.o.), caused no emetic episodes (retching and vomiting). Some behavioral changes (flattened posture, lip licking and backward walking) were observed and classified as mild. At 10 mg/kg in 2/6 ferrets, some retching but no frank emesis was observed along with salivation and behavioral changes (scored as mild or moderate). At the highest dose tested (30mg/kg) moderate to marked emesis was observed in 3/4 animals along with pronounced behavioral changes. These data are summarized in Table m.
  • Numbers in parentheses refer to the number of animals that responded The numbers of animals in each group range from 4-22.
  • TI therapeutic index
  • Table IV Summary of the effective doses (ED 5 ⁇ for inhibition of LPS-induced pulmonary neutrophilia and induction of emesis and the therapeutic index derived from these values.
  • EXAMPLE 9 200 MG DOSAGE CAPSULE Table V illustrates a batch formulation and single dosage formulation for a 200 mg
  • Compound A single dose unit i.e., about 40 percent by weight, in a size #0 capsule.
  • the pregelatinized corn starch (SPRESS B-820) and Compound A components are passed through a 710 ⁇ m screen and then are loaded into a Diffusion Mixer with a baffle insert and blended for 15 minutes.
  • the magnesium stearate is passed through a 210 ⁇ m screen and is added to the Diffusion Mixer.
  • the blend is then encapsulated in a size #0 capsule, 500 mg per capsule (8400 capsule batch size) using a Dosator type capsule filling machine.
  • Table VI illustrates a batch formulation and a single dose unit formulation containing 100 mg of Compound A.
  • the microcrystalline cellulose, croscarmellose sodium, and Compound A components are passed through a #30 mesh screen (about 430 ⁇ to about 655 ⁇ ).
  • the Pluronic F-68® (manufactured by JRH Biosciences, Inc. of Lenexa, KS) surfactant is passed through a #20 mesh screen (about 457 ⁇ to about 1041 ⁇ ).
  • the Pluronic F-68® surfactant and 0.5 kgs of croscarmellose sodium are loaded into a 16 qt. twin shell tumble blender and are mixed for about 5 minutes. The mix is then transferred to a 3 cubic foot twin shell tumble blender where the microcrystalline cellulose is added and blended for about 5 minutes. The thalidomide is added and blended for an additional 25 minutes.
  • This pre-blend is passed through a roller compactor with a hammer mill attached at the discharge of the roller compactor and moved back to the tumble blender.
  • the remaining croscarmellose sodium and magnesium stearate is added to the tumble blender and blended for about 3 minutes.
  • the final mixture is compressed on a rotary tablet press with 250 mg per tablet (200,000 tablet batch size).
  • a concentrate is prepared by combining Compound A, and a 12.6 kg portion of the trichloromonofluoromethane in a sealed stainless steel vessel equipped with a high shear mixer. Mixing is carried out for about 20 minutes.
  • the bulk suspension is then prepared in the sealed vessel by combining the concentrate with the balance of the propellants in a bulk product tank that is temperature controlled to 21° to 27 °C. and pressure controlled to 2.8 to 4.0 BAR.
  • 17 ml aerosol containers which have a metered valve which is designed to provide 100 inhalations of the composition of the invention. Each container is provided with the following:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)

Abstract

Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (-) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discused. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.

Description

(+)-2-[l-(3-ETHOXY-4-METHOXYPHENYL)-
2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-l,3-DIONE:
METHODS OF USING AND COMPOSITIONS THEREOF
1. FIELD OF INVENTION
The invention relates to methods of using and compositions comprising the (+) enantiomer of 2-[ 1 -(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline- 1 ,3-dione.
2. BACKGROUND OF THE INVENTION
Tumor necrosis factor alpha, (TNF-α) is a cytokine that is released primarily by mononuclear phagocytes in response to immunostimulators. TNF-α is capable of enhancing most cellular processes, such as differentiation, recruitment, proliferation, and proteolytic degradation. At low levels, TNF-α confers protection against infective agents, tumors, and tissue damage. But TNF-α also has a role in many diseases. When administered to mammals or humans, TNF-α causes or aggravates inflammation, fever, cardiovascular effects, hemonhage, coagulation, and acute phase responses similar to those seen during acute infections and shock states. Enhanced or unregulated TNF-α production has been implicated in a number of diseases and medical conditions, for example, cancers, such as solid tumors and blood-born tumors; heart disease, such as congestive heart failure; and viral, genetic, inflammatory, allergic, and autoimmune diseases.
Adenosine 3 ',5 '-cyclic monophosphate (cAMP) also plays a role in many diseases and conditions, such as but not limited to asthma and inflammation, and other conditions (Lowe and Cheng, Drugs of the Future, 17(9), 799-807, 1992). It has been shown that the elevation of cAMP in inflammatory leukocytes inhibits their activation and the subsequent release of inflammatory mediators, including TNF-α and NF-κB. Increased levels of cAMP also leads to the relaxation of airway smooth muscle.
It is believed that the primary cellular mechanism for the inactivation of cAMP is the breakdown of cAMP by a family of isoenzymes refened to as cyclic nucleotide phosphodiesterases (PDE) (Beavo and Reitsnyder, Trends in Pharm., 11, 150-155, 1990). There are eleven known PDE families. It is recognized, for example, that the inhibition of PDE type IV is particularly effective in both the inhibition of inflammatory mediator release and the relaxation of airway smooth muscle (Verghese, et al., Journal of Pharmacology and Experimental Therapeutics, 272(3), 1313-1320, 1995). Thus, compounds that inhibit PDE4 (PDE IV) specifically, may inhibit inflammation and aid the relaxation of airway smooth muscle with a minimum of unwanted side effects, such as cardiovascular or anti-platelet effects. Currently used PDE4 inhibitors lack the selective action at acceptable therapeutic doses.
Cancer is a particularly devastating disease, and increases in blood TNF-α levels are implicated in the risk of and the spreading of cancer. Normally, in healthy subjects, cancer cells fail to survive in the circulatory system, one of the reasons being that the lining of blood vessels acts as a barrier to tumor-cell extravasation. But increased levels of cytokines have been shown to substantially increase the adhesion of cancer cells to endothelium in vitro. One explanation is that cytokines, such as TNF-α, stimulate the biosynthesis and expression of a cell surface receptors called ELAM-1 (endothelial leukocyte adhesion molecule). ELAM-1 is a member of a family of calcium-dependent cell adhesion receptors, known as LEC-CAMs, which includes LECAM-1 and GMP-140. During an inflammatory response, ELAM-1 on endothelial cells functions as a "homing receptor" for leukocytes. Recently, ELAM-1 on endothelial cells was shown to mediate the increased adhesion of colon cancer cells to endothelium treated with cytokines (Rice et al. , 1989, Science 246:1303-1306).
Inflammatory diseases such as arthritis, related arthritic conditions (e.g., osteoarthritis and rheumatoid arthritis), inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis), sepsis, psoriasis, atopic dermatitis, contact dermatitis, and chronic obstructive pulmonary disease, chronic inflammatory pulmonary diseases are also prevalent and problematic ailments. TNF-α plays a central role in the inflammatory response and the administration of their antagonists block chronic and acute responses in animal models of inflammatory disease.
Enhanced or unregulated TNF-α production has been implicated in viral, genetic, inflammatory, allergic, and autoimmune diseases. Examples of such diseases include but are not limited to: HIV; hepatitis; adult respiratory distress syndrome; bone-resorption diseases; chronic obstructive pulmonary diseases; chronic pulmonary inflammatory diseases; asthma, dermatitis; cystic fibrosis; septic shock; sepsis; endotoxic shock; hemodynamic shock; sepsis syndrome; post ischemic reperfusion injury; meningitis; psoriasis; fibrotic disease; cachexia; graft rejection; auto-immune disease; rheumatoid spondylitis; arthritic conditions, such as rheumatoid arthritis and osteoarthritis; osteoporosis; Crohn's disease; ulcerative colitis; inflammatory-bowel disease; multiple sclerosis; systemic lupus erythrematosus; ENL in leprosy; radiation damage; asthma; and hyperoxic alveolar injury. Tracey et al, 1987, Nature 330:662-664 and Hinshaw et al, 1990, Czrc. Shock 30:279-292 (endotoxic shock); Dezube et al, 1990, Lancet, 335:662 (cachexia ); Millar et al, 1989, Lancet 2:712-714 and Fenai-Baliviera et al, 1989, Arch. Surg. 124:1400-1405 (adult respiratory distress syndrome); Bertolini et al, 1986, Nature 319:516-518, Johnson et al.,1989, Endocrinology 124:1424-1427, Holler et al, 1990, Blood 75:1011-1016, and Grau et al, 1989, N. Engl. J. Med. 320:1586-1591 (bone resorption diseases); Pignet et al, 1990, Nature, 344:245-247, Bissonnette et al, 1989, Inflammation 13:329-339 and Baughman et al, 1990, J. Lab. Clin. Med. 115:36-42 (chronic pulmonary inflammatory diseases); Elliot et al, 1995, Int. J. Pharmac. 17:141-145 (rheumatoid arthritis); von Dullemen et α/., 1995, Gastroenterology, 109:129-135 (Crohn's disease); Duh et al, 1989, Proc. Nat. Acad. Sci. 86:5974-5978, Poll et al, 1990, Proc. Nat. Acad. Sci. 87:782-785, Monto et al, 1990, Blood 79:2670, Clouse et al, 1989, J. Immunol. 142, 431-438, Poll et al, 1992, AIDS Res. Hum. Retrovirus, 191-197, Poli et al. 1990, Proc. Natl Acad. Sci. 87:782-784, Folks et al, 1989, PΝAS 86:2365-2368 (HIV and opportunistic infections resulting from HIV).
Pharmaceutical compounds that can block the activity or inhibit the production of certain cytokines, including TΝF-α, may be beneficial therapeutics. Many small-molecule inhibitors have demonstrated an ability to treat or prevent inflammatory diseases implicated by TΝF-α (for a review, see Lowe, 1998 Exp. Opin. Ther. Patents 8:1309-1332). One such class of molecules are the substituted phenethylsulfones described in United States patent number 6,020,358.
SUMMARY OF THE INVENTION
This invention relates to methods of treating diseases and disorders utilizing an enantiomer of a substituted phenethylsulfone compound and pharmaceutically acceptable salts, hydrates, solvates, clathrates, prodrugs and polymorphs thereof and methods for reducing the level of cytokines and their precursors in mammals. The invention also relates to pharmaceutical compositions comprising an enantiomer of 2-[l-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline- 1 ,3-dione and a pharmaceutically acceptable carrier. The invention further relates to an enantiomer of 2-[l- (3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione substantially free of its other enantiomer.
This invention particularly relates to the (+) enantiomer of 2-[l-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl] -4-acetylaminoisoindoline- 1 ,3 -dione. This compound is believed to have increased potency and other benefits as compared to its racemate — 2-[l-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline-l,3-dione. The invention encompasses the use of the (+) enantiomer of 2-[l-(3-Ethoxy- 4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione for treating or preventing diseases or disorders ameliorated by the inhibition of TNF-α production in mammals. In certain embodiments, this treatment includes the reduction or avoidance of adverse effects. Such disorders include, but are not limited to, cancers, including, but not limited to cancer of the head, thyroid, neck, eye, skin, mouth, throat, esophagus, chest, bone, blood, bone manow, lung, colon, sigmoid, rectum, stomach, prostate, breast, ovaries, kidney, liver, pancreas, brain, intestine, heart, adrenal, subcutaneous tissue, lymph nodes, heart, and combinations thereof. Specific cancers that can be treated by this method are multiple myeloma, malignant melanoma, malignant glioma, leukemia and solid tumors. The invention also encompasses the use of the (+) enantiomer of 2-[l-(3- Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione in the treatment or prevention of heart disease, including, but not limited to congestive heart failure, cardiomyopathy, pulmonary edema, endotoxin-mediated septic shock, acute viral myocarditis, cardiac allograft rejection, and myocardial infarction.
The invention also encompasses the use of the (+) enantiomer of 2-[l-(3- Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline- 1 ,3-dione to treat diseases or disorders ameliorated by the inhibition of PDE4. For example, the compounds and compositions of the invention maybe useful to treat or prevent viral, genetic, inflammatory, allergic, and autoimmune diseases. Examples of such diseases include, but are not limited to: HIV; hepatitis; adult respiratory distress syndrome; bone-resorption diseases; chronic obstructive pulmonary diseases; chronic pulmonary inflammatory diseases; dermatitis; inflammatory skin disease, atopic dermatitis, cystic fibrosis; septic shock; sepsis; endotoxic shock; hemodynamic shock; sepsis syndrome; post ischemic reperfusion injury; meningitis; psoriasis; fibrotic disease; cachexia; graft rejection including graft versus host disease; auto-immune disease; rheumatoid spondylitis; arthritic conditions, such as rheumatoid arthritis and osteoarthritis; osteoporosis; Crohn's disease; ulcerative colitis; inflammatory-bowel disease; multiple sclerosis; systemic lupus erythrematosus; erythema nodosum leprosum (ENL) in leprosy; radiation damage; asthma; and hyperoxic alveolar injury.
In yet another embodiment, the stereomerically pure (+) enantiomer of 2-[l- (3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione is also useful in the treatment or prevention of microbial infections or the symptoms of microbial infections including, but not limited to, bacterial infections, fungal infections, malaria, mycobacterial infection, and opportunistic infections resulting from HIV. The invention further encompasses pharmaceutical compositions and single unit dosage forms comprising an enantiomer of 2-[l-(3-Ethoxy-4-methoxyphenyl)-2- methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione and pharmaceutically acceptable polymorphs, prodrugs, salts, hydrates, clathrates, and solvates thereof. In a separate embodiment, the invention encompasses the (+) enantiomer of
2-[l-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3- dione. hi a further embodiment, the invention encompasses a method of producing a stereomerically pure enantiomer of 2-[l-(3-Ethoxy-4-methoxyphenyl)-2- methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione which comprises contacting l-(3-Ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethylamine with a chiral amino acid and contacting the product of the first step with
N-(l,3-Dioxo-l,3-dihydro-isobenzofuran-4-yl)-acetamide. In a related embodiment the invention encompasses a chiral salt of 1 -(3-Ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethylamine.
3.1. BRIEF DESCRIPTION OF THE FIGURES
FIG 1. illustrates the preparation of the (+) enantiomer of 2-[l-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione. FIG 2. illustrates the effect of the enantiomer of the invention on LPS- induced neutrophilia in the lungs of conscious fenets.
3.2. DEFINITIONS
As used herein, term "Compound A" refers to an enantiomerically pure form of2-[l-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3- dione which comes off of an HPLC column at about 25.4 minutes when that column is a 150 mm x 4.6 mm Ultron Chiral ES-OVS chiral HPLC column (Agilent Technology), the eluent is 15:85 ethanol: 20 mM KH2PO at pH 3.5, and the observation wavelength is 240 nm. The H NMR spectrum of compound A is substantially as follows: δ(CDCl3):1.47 (t, 3H), 2.26 (s, 3H), 2.87 (s, 3H), 3.68-3.75 (dd, IH), 3.85 (s, 3H), 4.07-4.15 (q, 2H), 4.51-
4.61 (dd, IH), 5.84-5.90 (dd, IH), 6.82-8.77 (m, 6H), 9.46 (s, IH). The 13C NMR spectrum of Compound A is substantially as follows δ(DMSO-d6): 14.66, 24.92, 41.61, 48.53, 54.46, 55.91, 64.51, 111.44, 112.40, 115.10, 118.20, 120.28, 124.94, 129.22, 131.02, 136.09, 137.60, 148.62, 149.74, 167.46, 169.14, 169.48. Compound A dissolved in methanol also rotates plane polarized light in the (+) direction. Without being limited by theory, Compound A is believed to be S-{2-[l-(3- ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione}, which has the following structure:
Figure imgf000007_0001
As used herein, the term "patient" refers to a mammal, particularly a human. As used herein, the term "pharmaceutically acceptable salts" refer to salts prepared from pharmaceutically acceptable non- toxic acids or bases including inorganic acids and bases and organic acids and bases. Suitable pharmaceutically acceptable base addition salts for the compound of the present invention include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, N,N'-dibenzylethylenediamine, chloroprocaine, cholme, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. Suitable non-toxic acids include, but are not limited to, inorganic and organic acids such as acetic, alginic, anthranilic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, formic, fumaric, furoic, galacturonic, gluconic, glucuronic, glutamic, glycolic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phenylacetic, phosphoric, propionic, salicylic, stearic, succinic, sulfanilic, sulfuric, tartaric acid, and p-toluenesulfonic acid. Specific non-toxic acids include hydrochloric, hydrobromic, phosphoric, sulfuric, and methanesulfonic acids. Examples of specific salts thus include hydrochloride and mesylate salts. As used herein and unless otherwise indicated, the term "prodrug" means a derivative of a compound that can hydrolyze, oxidize, or otherwise react under biological conditions (in vitro or in vivo) to provide the compound. Examples of prodrugs include, but are not limited to, derivatives and metabolites of Compound A that include biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues. Prodrugs can typically be prepared using well-known methods, such as those described by 1 Burger's Medicinal Chemistry and Drug Discovery, 172-178, 949-982 (Manfred E. Wolff erf., 5th ed. 1995).
As used herein and unless otherwise indicated, the tenns "biohydrolyzable amide," "biohydrolyzable ester," "biohydrolyzable carbamate," "biohydrolyzable carbonate," "biohydrolyzable ureide," "biohydrolyzable phosphate" mean an amide, ester, carbamate, carbonate, ureide, or phosphate, respectively, of a compound that either: 1) does not interfere with the biological activity of the compound but can confer upon that compound advantageous properties in vivo, such as uptake, duration of action, or onset of action; or 2) is biologically inactive but is converted in vivo to the biologically active compound. Examples of biohydrolyzable esters include, but are not limited to, lower alkyl esters, alkoxyacyloxy esters, alkyl acylamino alkyl esters, and choline esters. Examples of biohydrolyzable amides include, but are not limited to, lower alkyl amides, α-amino acid amides, alkoxyacyl amides, and alkylaminoalkylcarbonyl amides. Examples of biohydrolyzable carbamates include, but are not limited to, lower alkylamines, substituted ethylenediamines, aminoacids, hydroxyalkylamines, heterocyclic and heteroaromatic amines, and polyether amines.
As used herein and unless otherwise indicated, the term "stereomerically pure" means a composition that comprises one stereoisomer of a compound and is substantially free of other stereoisomers of that compound. For example, a stereomerically pure composition of a compound having one chiral center will be substantially free of the opposite enantiomer of the compound. A stereomerically pure composition of a compound having two chiral centers will be substantially free of other diastereomers of the compound. A typical stereomerically pure compound comprises greater than about 80% by weight of one stereoisomer of the compound and less than about 20% by weight of other stereoisomers of the compound, more preferably greater than about 90% by weight of one stereoisomer of the compound and less than about 10% by weight of the other stereoisomers of the compound, even more preferably greater than about 95% by weight of one stereoisomer of the compound and less than about 5% by weight of the other stereoisomers of the compound, and most preferably greater than about 97% by weight of one stereoisomer of the compound and less than about 3% by weight of the other stereoisomers of the compound.
As used herein and unless otherwise indicated, the term "enantiomerically pure" means a stereomerically pure composition of a compound having one chiral center. As used herein, term "adverse effects" includes, but is not limited to gastrointestinal, renal and hepatic toxicities, leukopenia, increases in bleeding times due to, e.g., thrombocytopenia, and prolongation of gestation, nausea, vomiting, somnolence, asthenia, dizziness, teratogenicity, extra-pyramidal symptoms, akathisia, cardiotoxicity including cardiovascular disturbances, inflammation, male sexual dysfunction, and elevated serum liver enzyme levels. The term "gastrointestinal toxicities" includes but is not limited to gastric and intestinal ulcerations and erosions. The term "renal toxicities" includes but is not limited to such conditions as papillary necrosis and chronic interstitial nephritis.
As used herein and unless otherwise indicated, the phrases "reduce or avoid adverse effects" and "reducing or avoiding adverse effects" mean the reduction of the severity of one or more adverse effects as defined herein.
It should be noted that if there is a discrepancy between a depicted structure and a name given that structure, the depicted structure is to be accorded more weight. In addition, if the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of it.
4. DETAILED DESCRIPTION OF THE INVENTION
This invention relates to stereomerically pure Compound A, which is an enantiomer of 2-[ 1 -(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline-l,3-dione, substantially free of its other enantiomer, as well as novel methods using, and compositions comprising stereomerically pure Compound A. For example, the present invention encompasses the in vitro and in vivo use of Compound A, and the incorporation of Compound A into pharmaceutical compositions and single unit dosage forms useful in the treatment and prevention of a variety of diseases and disorders. Diseases and disorders which are ameliorated by the reduction of levels of TNF-α or inhibition of PDE4 are well known in the art and are described herein. Specific methods of the invention reduce or avoid the adverse effects associated with compounds used as TNF-α inhibitor. Other specific methods of the invention reduce or avoid the adverse effects associated with use of racemic 2-[l-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline-l,3-dione. Specific methods of the invention include methods of treating or preventing diseases and disorders including, but not limited to, solid tumor cancers, blood-born cancers and inflammatory diseases.
Pharmaceutical and dosage forms of the invention, which comprise Compound A or a pharmaceutically acceptable polymorph, prodrug, salt, clathrate, solvate or hydrate thereof, can be used in the methods of the invention.
Without being limited by theory, it is believed that Compound A can inhibit TNF-α production. Consequently, a first embodiment of the invention relates to a method of inhibiting TNF-α production which comprises contacting a cell exhibiting abnormal TNF-α production with an effective amount of stereomerically pure Compound A, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof. In a particular embodiment, the invention relates to a method of inhibiting TNF-α production which comprises contacting a mammalian cell exhibiting abnormal TNF-α production with an effective amount of stereomerically pure Compound A, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
The invention also relates to a method of treating or preventing disorders ameliorated by the reduction of levels of TNF-α in a patient which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of stereomerically pure compound A, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
A further embodiment of the invention relates to a method of treating or preventing cancer, including but not limited to, solid tumor, blood-born tumor, leukemias, and in particular, multiple myeloma in a patient which comprises administering to a patient in need of such treatment or prevention a therapeutically effective amount of stereomerically pure compound A, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof; in particular wherein the patient is a mammal.
In another embodiment, the invention relates to a method of inhibiting PDE4 which comprises contacting PDE4 with an effective amount of stereomerically pure Compound A, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
In another embodiment, the invention relates to a method of controlling cAMP levels in a cell which comprises contacting a cell with an effective amount of stereomerically pure Compound A, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof. As used herein the term "controlling cAMP levels" includes preventing or reducing the rate of the breakdown of Adenosine 3',5'-cyclic monophosphate (cAMP) in a cell or increasing the amount of Adenosine 3',5'-cyclic monophosphate present in a cell, preferably a mammalian cell, more preferably a human cell, hi a particular method, the rate of cAMP breakdown is reduced by about 10, 25, 50, 100, 200, or 500 percent as compared to the rate in comparable cells which have not been contacted with a compound of the invention.
A further embodiment of the invention relates to a method of treating or preventing diseases or disorders ameliorated by the inhibition of PDE4 in a patient which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of stereomerically pure Compound A, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof. Disorders ameliorated by the inhibition of PDE4 include, but are not limited to, asthma, inflammation (e.g., inflammation due to reperfusion), chronic or acute obstructive pulmonary diseases, chronic or acute pulmonary inflammatory diseases, inflammatory bowel disease, Crohn's Disease, Bechet's Disease, or colitis.
A further embodiment of the invention relates to a method of treating or preventing depression, asthma, inflammation (e.g., contact dermatitis, atopic dermatitis, psoriais, rheumatoid arthritis, osteoarthritis, inflammatory skin disease, inflammation due to reperfusion), chronic or acute obstructive pulmonary diseases, chronic or pulmonary inflammatory diseases, inflammatory bowel disease, Crohn's Disease, Bechet's Disease or colitis in a patient which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of stereomerically pure Compound A, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof; in particular wherein the patient is a mammal. A separate embodiment of the invention encompasses methods of treating or preventing Myelodysplastic syndrome (MDS) which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of stereomerically pure Compound A, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof. MDS refers to a diverse group of hematopoietic stem cell disorders. MDS is characterized by a cellular marrow with impaired morphology and maturation (dysmyelopoiesis), peripheral blood cytopenias, and a variable risk of progression to acute leukemia, resulting from ineffective blood cell production. See The Merck Manual 953 (17th ed. 1999) and List et al, 1990, J. Clin. Oncol. 8:1424.MDS A separate embodiment of the invention encompasses methods of treating or preventing Myeloprohferative disease (MPD) which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of stereomerically pure Compound A, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clatlirate, or prodrug thereof. Myeloprohferative disease (MPD) refers to a group of disorders characterized by clonal abnormalities of the hematopoietic stem cell. See e.g., Current Medical Diagnosis & Treatment, pp. 499 (37th ed., Tierney et al. ed, Appleton & Lange, 1998).
The invention also encompasses a method of treating, preventing or managing complex regional pain syndrome, which comprises administering to a patient in need of such treatment, prevention or management a therapeutically or prophylactically effective amount of a stereomerically pure Compound A, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, hi a specific embodiment, the administration is before, during or after surgery or physical therapy directed at reducing or avoiding a symptom of complex regional pain syndrome in the patient. hi particular methods of the invention, stereomerically pure Compound A, or a pharmaceutically acceptable polymorph, prodrug, salt, solvate, hydrate, or clathrate thereof, is adjunctively administered with at least one additional therapeutic agent. Examples of additional therapeutic agents include, but are not limited to, anti-cancer drugs, anti-inflammatories, antihistamines and decongestants.
4.1. SYNTHESIS AND PREPARATION
Racemic 2- [ 1 -(3 -Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl] -4- acetylaminoisoindoline-l,3-dione is readily prepared using the methods in United States Patent No. 6,020,358, which is incorporated herein by reference.
Compound A can be isolated from the racemic compound by techniques known in the art. Examples include, but are not limited to, the formation of chiral salts and the use of chiral or high performance liquid chromatography "HPLC" and the formation and crystallization of chiral salts. See, e.g., Jacques, J., et al, Enantiomers, Racemates and Resolutions (Wiley-Interscience, New York, 1981); Wilen, S. H., et al, Tetrahedron
33:2725 (1977); Eliel, E. L., Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, S. H., Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN, 1972).
In a specific method, Compound A is synthesized from 3-acetamidophthalic anhydride and a chiral amino acid salt of (S)-2-(3-ethoxy-4-methoxyphenyl)-l- (methylsulphonyl)-eth-2-ylamine. Chiral amino acid salts of
(S)-2-(3-ethoxy-4-methoxyphenyl)-l-(methylsulphonyl)-eth-2-ylamine include, but not limited to salts formed with the L isomers of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosme, valine, ornithine, 4-aminobutyric acid, 2 amino isobutyric acid, 3 amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, and N-acetyl-leucine. A specific chiral amino acid salt is (S)-2-(3-ethoxy-4-methoxyphenyl)- 1 -(methylsulphonyl)-eth-2-ylamine N-acetyl-L-leucine salt, which is resolved from 2-(3-ethoxy-4-methoxyphenyl)-l-(methylsulphonyl)-eth-2- ylamine and N-acetyl-L-leucine in methanol.
4.2. METHODS OF TREATMENT
The invention encompasses methods of treating and preventing diseases or disorders ameliorated by the reduction of levels of TNF-α in a patient which comprise administering to a patient in need of such treatment or prevention a therapeutically effective amount of stereomerically pure Compound A, or a phannaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
Disorders ameliorated by the inhibition of TNF-α include, but are not limited to: heart disease, such as congestive heart failure, cardiomyopathy, pulmonary edema, endotoxin-mediated septic shock, acute viral myocarditis, cardiac allograft rejection, and myocardial infarction; solid tumors, including but not limited to, sarcoma, carcinomas, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothehoma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, Kaposi's sarcoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma; and blood-born tumors including but not limited to, acute lymphoblastic leukemia "ALL", acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute myeloblastic leukemia "AML", acute promyelocytic leukemia "APL", acute monoblastic leukemia, acute erythroleukemic leukemia, acute megakaryoblastic leukemia, acute myelomonocytic leukemia, acute nonlymphocyctic leukemia, acute undifferentiated leukemia, chronic myelocytic leukemia "CML", chronic lymphocytic leukemia "CLL", hairy cell leukemia, multiple myeloma and acute and chronic leukemias, for example, lymphoblastic, myelogenous, lymphocytic, and myelocytic leukemias.
Specific methods of the invention further comprise the administration of an additional therapeutic agent (i.e., a therapeutic agent other than Compound A). Examples of additional therapeutic agents include, but are not limited to, anti-cancer drugs such as, but are not limited to: alkylating agents, nitrogen mustards, ethylenimines, methylmelamines, alkyl sulfonates, nitrosoureas, triazenes, folic acid analofs, pyrimidine analogs, purine analogs, vinca alkaloids, epipodophyllotoxins, antibiotics, topoisomerase inhibitors and anti-cancer vaccines. Specific additional therapeutic agents include, but are not limited to: acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; alfretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cisplatin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; dactinomycin; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; docetaxel; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflornithine hydrochloride; elsamitracin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; ilmofosine; interleukin II (including recombinant interleukin π, or rIL2), interferon alfa-2a; interferon alfa-2b; interferon alfa-nl ; interferon alfa-n3; interferon beta-I a; interferon gamma-I b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazole; nogalamycin; ormaplatin; oxisuran; paclitaxel; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermamum hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafiir; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride. Other anti-cancer drugs include, but are not limited to: 20-epi-l,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein- 1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin DI derivatives; balanol; batimastat; BCR ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin
B; betulinic acid; bFGF inhibitor; bicalutamide; bisanfrene; bisaziridinylspermine; bisnafide; bisfratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorlns; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin
B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; dihydrotaxol, 9-; dioxamycin; diphenyl spiromustine; docetaxel; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor- 1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fϊbroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor
1-based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nifroxide antioxidant; nitrullyn; O6-benzylguanine; ocfreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel; paclitaxel analogues; paclitaxel derivatives; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; penfrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists; raltifrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RU retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone Bl; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen binding protein; sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tefrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin
B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer. The invention further encompasses a method of treating or preventing diseases or disorders ameliorated by the inhibition of PDE4 in a patient which comprise administering to a patient in need of such treatment or prevention a therapeutically effective amount of stereomerically pure Compound A, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof. Disorders ameliorated by the inhibition of PDE4 include, but are not limited to, asthma, inflammation, chronic or acute obstructive pulmonary disease, chronic or acute pulmonary inflammatory disease, inflammatory bowel disease, Crohn's Disease, Bechet's Disease, colitis, ulcerative colitis and arthritis or inflammation due to reperfusion. In a prefened embodiment, the disease or disorder to be treated or prevented is chronic obstructive pulmonary disease.
Specific methods of the invention can comprise the administration of an additional therapeutic agent such as, but not limited to, anti-inflammatory drugs, antihistamines and decongestants. Examples of such additional therapeutic agents include, but are not limited to: antihistamines including, but not limited to, ethanolamines, ethylenediamines, piperazines, and phenothiazines; antinflammatory drugs; NSAIDS, including, but not limited to, aspirin, sahcylates, acetominophen, indomethacin, sulindac, etodolac, fenamates, tolmetin, ketorolac, diclofenac, ibuprofen, naproxen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin, piroxicam, meloxicam, pyrazolon derivatives; and steriods including, but not limited to, cortical steroids and adrenocortical steroids. Specific methods of the invention avoid or reduce drug-drug interactions and other adverse effects associated with agents used in the treatment of such disorders, including racemic substituted phenylethylsulfones. Without being limited by any theory, stereomerically pure Compound A may further provide an overall improved therapeutic effectiveness, or therapeutic index, over racemic 2-[l-(3-Ethoxy-4-methoxyphenyl)-2- methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione. For example, a smaller amount of the drug may in some circumstances be administered to attain the same level of effectiveness.
As stated above, the active compound of the invention (i.e., Compound A) may be used in the treatment or prevention of a wide range of diseases and conditions. The magnitude of a prophylactic or therapeutic dose of a particular active ingredient of the invention in the acute or chronic management of a disease or condition will vary, however, with the nature and severity of the disease or condition, and the route by which the active ingredient is administered. The dose, and perhaps the dose frequency, will also vary according to the age, body weight, and response of the individual patient. Suitable dosing regimens can be readily selected by those skilled in the art with due consideration of such factors, hi general, the recommended daily dose range for the conditions described herein lie within the range of from about 1 mg to about 1000 mg per day, given as a single once-a- day dose preferably as divided doses throughout a day. More specifically, the daily dose is administered twice daily in equally divided doses. Specifically, a daily dose range should be from about 5 mg to about 500 mg per day, more specifically, between about 10 mg and about 200 mg per day. Specifically, the daily dose may be administered in 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 50 mg, orlOO mg dosage forms. In managing the patient, the therapy should be initiated at a lower dose, perhaps about 1 mg to about 25 mg, and increased if necessary up to about 200 mg to about 1000 mg per day as either a single dose or divided doses, depending on the patient's global response. Alternatively, the daily dose is from 0.01 mg/kg to 100 mg/kg.
It may be necessary to use dosages of the active ingredient outside the ranges disclosed herein in some cases, as will be apparent to those of ordinary skill in the art. Furthermore, it is noted that the clinician or treating physician will know how and when to interrupt, adjust, or terminate therapy in conjunction with individual patient response.
The phrases "therapeutically effective amount", "prophylactically effective amount" and "therapeutically or prophylactically effective amoxint," as used herein encompasses the above described dosage amounts and dose frequency schedules. Different therapeutically effective amounts may be applicable for different diseases and conditions, as will be readily known by those of ordinary skill in the art. Similarly, amounts sufficient to treat or prevent such disorders, but insufficient to cause, or sufficient to reduce, adverse effects associated with racemic 2-[l-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-l,3-dione are also encompassed by the above described dosage amounts and dose frequency schedules.
4.3. PHARMACEUTICAL COMPOSITIONS
Pharmaceutical compositions and single unit dosage forms comprising Compound A, or a pharmaceutically acceptable polymorph, prodrug, salt, solvate, hydrate, or clathrate thereof, are encompassed by the invention. Individual dosage forms of the invention may be suitable for oral, mucosal (including rectal, nasal, or vaginal), parenteral (including subcutaneous, intramuscular, bolus injection, intraarterial, or intravenous), sublingual, transdermal, buccal, or topical administration.
Pharmaceutical compositions and dosage forms of the invention comprise stereomerically pure Compound A, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof. Pharmaceutical compositions and dosage forms of the invention typically also comprise one or more pharmaceutically acceptable excipients.
A particular pharmaceutical composition encompassed by this embodiment comprises stereomerically pure Compound A, or a pharmaceutically acceptable polymorph, prodrug, salt, solvate, hydrate, or clathrate thereof, and at least one additional therapeutic agent. Examples of additional therapeutic agents include, but are not limited to: anti-cancer drugs and anti-inflammation therapies including, but not limited to, those listed above in section 4.2.
Single unit dosage forms of the invention are suitable for oral, mucosal (e.g., nasal, sublingual, vaginal, buccal, or rectal), parenteral (e.g., subcutaneous, intravenous, bolus injection, intramuscular, or intraarterial), or transdermal administration to a patient. Examples of dosage forms include, but are not limited to: tablets; caplets; capsules, such as soft elastic gelatin capsules; cachets; troches; lozenges; dispersions; suppositories; ointments; cataplasms (poultices); pastes; powders; dressings; creams; plasters; solutions; patches; aerosols (e.g., nasal sprays or inhalers); gels; liquid dosage forms suitable for oral or mucosal administration to a patient, including suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in- water emulsions, or a water-in-oil liquid emulsions), solutions, and elixirs; liquid dosage forms suitable for parenteral administration to a patient; and sterile solids (e.g., crystalline or amorphous solids) that can be reconstituted to provide liquid dosage forms suitable for parenteral administration to a patient.
The composition, shape, and type of dosage forms of the invention will typically vary depending on their use. For example, a dosage form used in the acute treatment of inflammation or a related disorder may contain larger amounts of one or more of the active ingredients it comprises than a dosage form used in the chronic treatment of the same disease. Similarly, a parenteral dosage form may contain smaller amounts of one or more of the active ingredients it comprises than an oral dosage form used to treat the same disease or disorder. These and other ways in which specific dosage forms encompassed by this invention will vary from one another will be readily apparent to those skilled in the art. See, e.g., Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton PA (1990).
Typical pharmaceutical compositions and dosage forms comprise one or more excipients. Suitable excipients are well known to those skilled in the art of pharmacy, and non-limiting examples of suitable excipients are provided herein. Whether a particular excipient is suitable for incorporation into a pharmaceutical composition or dosage form depends on a variety of factors well known in the art including, but not limited to, the way in which the dosage form will be administered to a patient. For example, oral dosage forms such as tablets may contain excipients not suited for use in parenteral dosage forms. The suitability of a particular excipient may also depend on the specific active ingredients in the dosage form. Lactose-free compositions of the invention can comprise excipients that are well known in the art and are listed, for example, in the U.S. Pharmocopia (USP) SP (XXI)/NF (XVI). h general, lactose-free compositions comprise an active ingredient, a binder/filler, and a lubricant in pharmaceutically compatible and pharmaceutically acceptable amounts. Prefened lactose-free dosage forms comprise an active ingredient, microcrystalline cellulose, pre-gelatinized starch, and magnesium stearate.
This invention further encompasses anhydrous pharmaceutical compositions and dosage forms comprising active ingredients, since water can facilitate the degradation of some compounds. For example, the addition of water (e.g., 5%) is widely accepted in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf-life or the stability of formulations over time. See, e.g., Jens T. Carstensen, Drug Stability: Principles & Practice, 2d. Ed., Marcel Dekker, NY, NY, 1995, pp. 379-80. In effect, water and heat accelerate the decomposition of some compounds. Thus, the effect of water on a formulation can be of great significance since moisture and/or humidity are commonly encountered during manufacture, handling, packaging, storage, shipment, and use of formulations.
Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms that comprise lactose and at least one active ingredient that comprises a primary or secondary amine are preferably anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected.
An anhydrous pharmaceutical composition should be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are preferably packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g., vials), blister packs, and strip packs.
The invention further encompasses pharmaceutical compositions and dosage forms that comprise one or more compounds that reduce the rate by which an active ingredient will decompose. Such compounds, which are refened to herein as "stabilizers," include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers.
Like the amounts and types of excipients, the amounts and specific types of active ingredients in a dosage form may differ depending on factors such as, but not limited to, the route by which it is to be administered to patients. However, typical dosage forms of the invention comprise compound A, or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, polymoprh or prodrug thereof lie within the range of from about 1 mg to about 1000 mg per day, given as a single once-a-day dose in the morning but preferably as divided doses throughout the day taken with food. More specifically, the daily dose is administered twice daily in equally divided doses. Specifically, a daily dose range should be from about 5 mg to about 500 mg per day, more specifically, between about 10 mg and about 200 mg per day. In managing the patient, the therapy should be initiated at a lower dose, perhaps about 1 mg to about 25 mg, and increased if necessary up to about 200 mg to about 1000 mg per day as either a single dose or divided doses, depending on the patient's global response.
4.3.1. ORAL DOSAGE FORMS
Pharmaceutical compositions of the invention that are suitable for oral administration can be presented as discrete dosage forms, such as, but are not limited to, tablets (e.g., chewable tablets), caplets, capsules, and liquids (e.g., flavored syrups). Such dosage forms contain predetermined amounts of active ingredients, and maybe prepared by methods of pharmacy well known to those skilled in the art. See generally, Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton PA (1990).
Typical oral dosage forms of the invention are prepared by combining the active ingredient(s) in an intimate admixture with at least one excipient according to conventional pharmaceutical compounding techniques. Excipients can take a wide variety of fonns depending on the form of preparation desired for administration. For example, excipients suitable for use in oral liquid or aerosol dosage forms include, but are not limited to, water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents. Examples of excipients suitable for use in solid oral dosage forms (e.g., powders, tablets, capsules, and caplets) include, but are not limited to, starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents.
Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid excipients are employed. If desired, tablets can be coated by standard aqueous or nonaqueous techniques. Such dosage forms can be prepared by any of the methods of pharmacy, hi general, pharmaceutical compositions and dosage forms are prepared by uniformly and intimately admixing the active ingredients with liquid carriers, finely divided solid carriers, or both, and then shaping the product into the desired presentation if necessary. For example, a tablet can be prepared by compression or molding.
Compressed tablets can be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as powder or granules, optionally mixed with an excipient. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. Examples of excipients that can be used in oral dosage forms of the invention include, but are not limited to, binders, fillers, disintegrants, and lubricants. Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, (e.g., Nos. 2208, 2906, 2910), microcrystalline cellulose, and mixtures thereof.
Examples of fillers suitable for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof. The binder or filler in pharmaceutical compositions of the invention is typically present in from about 50 to about 99 weight percent of the pharmaceutical composition or dosage form. Suitable forms of microcrystalline cellulose include, but are not limited to, the materials sold as AVICEL-PH-101, AVICEL-PH-103 ANICEL RC-581, ANICEL-PH-105 (available from FMC Corporation, American Viscose Division, Avicel Sales, Marcus Hook, PA), and mixtures thereof. An specific binder is a mixture of microcrystalline cellulose and sodium carboxymethyl cellulose sold as AVICEL RC-581. Suitable anhydrous or low moisture excipients or additives include AVICEL-PH-103™ and Starch 1500 LM.
Disintegrants are used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment. Tablets that contain too much disintegrant may disintegrate in storage, while those that contain too little may not disintegrate at a desired rate or under the desired conditions. Thus, a sufficient amount of disintegrant that is neither too much nor too little to detrimentally alter the release of the active ingredients should be used to form solid oral dosage forms of the invention. The amount of disintegrant used varies based upon the type of formulation, and is readily discernible to those of ordinary skill in the art. Typical pharmaceutical compositions comprise from about 0.5 to about 15 weight percent of disintegrant, specifically from about 1 to about 5 weight percent of disintegrant.
Disintegrants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums, and mixtures thereof.
Lubricants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, and mixtures thereof. Additional lubricants include, for example, a syloid silica gel (AEROSIL 200, manufactured by W.R. Grace Co. of Baltimore, MD), a coagulated aerosol of synthetic silica (marketed by Degussa Co. of Piano, TX), CAB-O-SIL (a pyrogenic silicon dioxide product sold by Cabot Co. of Boston, MA), and mixtures thereof. If used at all, lubricants are typically used in an amount of less than about 1 weight percent of the pharmaceutical compositions or dosage forms into which they are incorporated.
4.3.2. DELAYED RELEASE DOSAGE FORMS
Active ingredients of the invention can be administered by controlled release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U.S. Patent Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; and 4,008,719, 5,674,533, 5,059,595, 5,591,767, 5,120,548, 5,073,543, 5,639,476, 5,354,556, and 5,733,566, each of wliich is incorporated herein by reference. Such dosage forms can be used to provide slow or controlled-release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions. Suitable controlled-release formulations known to those of ordinary skill in the art, including those described herein, can be readily selected for use with the active ingredients of the invention. The invention thus encompasses single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled-release. All controlled-release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled counterparts. Ideally, the use of an optimally designed controlled-release preparation in medical treatment is characterized by a minimum of drug substance being employed to cure or control the condition in a minimum amount of time. Advantages of controlled-release formulations include extended activity of the drug, reduced dosage frequency, and increased patient compliance, h addition, controlled-release formulations can be used to affect the time of onset of action or other characteristics, such as blood levels of the drug, and can thus affect the occunence of side (e.g., adverse) effects.
Most controlled-release formulations are designed to initially release an amount of drug (active ingredient) that promptly produces the desired therapeutic effect, and gradually and continually release of other amounts of drug to maintain this level of therapeutic or prophylactic effect over an extended period of time. In order to maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body. Controlled-release of an active ingredient can be stimulated by various conditions including, but not limited to, pH, temperature, enzymes, water, or other physiological conditions or compounds.
4.3.3. PARENTERAL DOSAGE FORMS Parenteral dosage forms can be administered to patients by various routes including, but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and intraarterial. Because their administration typically bypasses patients' natural defenses against contaminants, parenteral dosage forms are preferably sterile or capable of being sterilized prior to administration to a patient. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions.
Suitable vehicles that can be used to provide parenteral dosage forms of the invention are well known to those skilled in the art. Examples include, but are not limited to: Water for hijection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
Compounds that increase the solubility of one or more of the active ingredients disclosed herein can also be incorporated into the parenteral dosage forms of the invention.
4.3.4. TRANSDERMAL, TOPICAL,
AND MUCOSAL DOSAGE FORMS
Transdermal, topical, and mucosal dosage forms of the mvention include, but are not limited to, ophthalmic solutions, sprays, aerosols, creams, lotions, ointments, gels, solutions, emulsions, suspensions, or other forms known to one of skill in the art. See, e.g., Remington's Pharmaceutical Sciences, 16th and 18th eds., Mack Publishing, Easton PA (1980 & 1990); and Introduction to Pharmaceutical Dosage Forms, 4th ed., Lea & Febiger, Philadelphia (1985). Dosage forms suitable for treating mucosal tissues within the oral cavity can be formulated as mouthwashes or as oral gels. Further, transdermal dosage forms include "reservoir type" or "matrix type" patches, which can be applied to the skin and worn for a specific period of time to permit the penetration of a desired amount of active ingredients.
Suitable excipients (e.g. , carriers and diluents) and other materials that can be used to provide transdermal, topical, and mucosal dosage forms encompassed by this mvention are well known to those skilled in the pharmaceutical arts, and depend on the particular tissue to which a given pharmaceutical composition or dosage form will be applied. With that fact in mind, typical excipients include, but are not limited to, water, acetone, ethanol, ethylene glycol, propylene glycol, butane- 1,3-diol, isopropyl myristate, isopropyl palmitate, mineral oil, and mixtures thereof to form lotions, tinctures, creams, emulsions, gels or ointments, which are non-toxic and pharmaceutically acceptable.
Moisturizers or humectants can also be added to pharmaceutical compositions and dosage forms if desired. Examples of such additional ingredients are well known in the art. See, e.g. , Remington 's Pharmaceutical Sciences, 16th and 18th eds., Mack Publishing, Easton PA (1980 & 1990). Depending on the specific tissue to be treated, additional components may be used prior to, in conjunction with, or subsequent to treatment with active ingredients of the invention. For example, penetration enhancers can be used to assist in delivering the active ingredients to the tissue. Suitable penetration enhancers include, but are not limited to: acetone; various alcohols such as ethanol, oleyl, and tetrahydrofuryl; alkyl sulfoxides such as dimethyl sulfoxide; dimethyl acetamide; dimethyl formamide; polyethylene glycol; pynolidones such as polyvinylpynolidone; Kollidon grades (Povidone, Polyvidone); urea; and various water-soluble or insoluble sugar esters such as Tween 80 (polysorbate 80) and Span 60 (sorbitan monostearate).
The pH of a pharmaceutical composition or dosage form, or of the tissue to which the pharmaceutical composition or dosage form is applied, may also be adjusted to improve delivery of one or more active ingredients. Similarly, the polarity of a solvent carrier, its ionic strength, or tonicity can be adjusted to improve delivery. Compounds such as stearates can also be added to pharmaceutical compositions or dosage forms to advantageously alter the hydrophilicity or lipophilicity of one or more active ingredients so as to improve delivery. In this regard, stearates can serve as a lipid vehicle for the formulation, as an emulsifying agent or surfactant, and as a delivery-enhancing or penetration-enhancing agent. Different salts, hydrates or solvates of the active ingredients can be used to further adjust the properties of the resulting composition.
4.3.5. KITS Typically, active ingredients of the invention are preferably not administered to a patient at the same time or by the same route of administration. This invention therefore encompasses kits which, when used by the medical practitioner, can simplify the administration of appropriate amounts of active ingredients to a patient.
A typical kit of the invention comprises a unit dosage form of compound A, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, polymorph or prodrug thereof, and a unit dosage form of a second active ingredient. Examples of second active ingredients include, but are not limited to, those listed in section 4.2 above.
Kits of the invention can further comprise devices that are used to administer the active ingredient(s). Examples of such devices include, but are not limited to, syringes, drip bags, patches, and inhalers.
Kits of the invention can further comprise pharmaceutically acceptable vehicles that can be used to administer one or more active ingredients. For example, if an active ingredient is provided in a solid form that must be reconstituted for parenteral administration, the kit can comprise a sealed container of a suitable vehicle in which the active ingredient can be dissolved to form a particulate-free sterile solution that is suitable for parenteral administration. Examples of pharmaceutically acceptable vehicles include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
5. EXAMPLES 5.1. EXAMPLE 1: SYNTHESIS OF 2-[l-(3-ETHOXY-4-
METHOXYPHENYL)-2-METHYLSULFONYLETHYLJ- 4-ACETYLAMINOISOINDOLINE-1.3-DIONE
A stfrred solution of l-(3-ethoxy-4-methoxyphenyl)- 2-methylsulfonylethylamine (l.Og, 3.7 mmol) and 3 -acetamidophthahc anhydride (751 mg, 3.66 mmol) in acetic acid (20 mL) was heated at reflux for 15 h. The solvent was removed in vacuo to yield an oil. Chromatography of the resulting oil yielded the product as a yellow solid (1.0 g, 59% yield): mp, 144°C; Η NMR (CDC13) δl.47 (t, J=7.0 Hz, 3H, CH3), 2.26 (s, 3H, CH3), 2.88 (s,3H, CH3), 3.75 (dd, J=4.4, 14.3 Hz, IH, CHH), 3.85 (s, 3H, CH3), 4.11 (q, J= 7 Hz, 2H, CH2), 5.87 (dd, J=4.3, 10.5 Hz, IH, NCH), 6.82-6.86 (m, IH, Ar),
7.09-7.11 (m, 2H, Ar), 7.47 (d, J= 7 Hz, IH., Ar), 7.64 (t, J= 8 Hz, IH, Ar), 8.74 (d, J= 8 Hz, IH, Ar), 9.49 (br s, IH, NH); 13C NMR (CDC13) 614.61, 24.85, 41.54, 48.44, 54.34, 55.85, 64.43, 111.37, 112.34, 115.04, 118.11, 120.21, 124.85, 129.17, 130.96, 136.01, 137.52, 148.54, 149.65, 167.38, 169.09, 169.40; Anal Calc'd. for C22H24NO7S: C, 57.38; H, 5.25; N, 6.08. Found: C, 57.31; H, 5.34; N, 5.83.
5.2. EXAMPLE 2: SYNTHESIS OF (+)2-[l-(3-ETHOXY-
4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]- 4-ACETYLAMINOISOINDOLINE-1.3-DIONE
Preparation of 3-aminopthalic acid
10% Pd/C (2.5 g), 3-nitrophthalic acid (75.0 g, 355 mmol) and ethanol (1.5 L) were charged to a 2.5 L Parr hydrogenator, under a nitrogen atmosphere. Hydrogen was charged to the reaction vessel for up to 55 psi. The mixture was shaken for 13 hours, maintaining hydrogen pressure between 50 and 55 psi. Hydrogen was released and the mixture was purged with nitrogen 3 times. The suspension was filtered through a celite bed and rinsed with methanol. The filtrate was concentrated in vacuo. The resulting solid was reslurried in ether and isolated by vacuum filtration. The solid was dried in vacua to a constant weight, affording 54 g (84% yield) of 3-aminopthalic acid as a yellow product. !H- NMR (DMSO-d6) δ: 3.17 (s, 2H), 6.67 (d, IH), 6.82 (d, IH), 7.17 (t, IH), 8-10 (brs, 2H). 13C-NMR(DMSO-d6)δ: 112.00, 115.32, 118.20, 131.28, 135.86, 148.82, 169.15, 170.09.
Preparation of 3-acetamidophthalic anhydride
A I L 3-necked round bottom flask was equipped with a mechanical stiner, thermometer, and condenser and charged with 3-aminophthalic acid (108 g, 596 mmol) and acetic anhydride (550 mL). The reaction mixture was heated to reflux for 3 hours and cooled to ambient temperature and further to 0-5 °C for another 1 hour. The crystalline solid was collected by vacuum filtration and washed with ether. The solid product was dried in vacua at ambient temperature to a constant weight, giving 75 g (61% yield) of 3- acetamidopthalic anhydride as a white product. Η-NMR (CDC13) δ: 2.21 (s, 3H), 7.76 (d, IH), 7.94 (t, IH), 8.42 (d, IH), 9.84 (s, IH).
Resolution of
2-(3-ethoxy-4-methoxyphenyl)-l-(methylsulphonyl)-eth-2-ylamine
A 3 L 3-necked round bottom flask was equipped with a mechanical stiner, thermometer, and condenser and charged with 2-(3-ethoxy-4-methoxyphenyl)-l - (methylsulphonyl)-eth-2-ylamine (137.0 g, 500 mmol), N-acetyl-L-leucine (52 g, 300 mmol), and methanol (1.0 L). The stfrred slurry was heated to reflux for 1 hour. The stined mixture was allowed to cool to ambient temperature and stirring was continued for another 3 hours at ambient temperature. The slurry was filtered and washed with methanol (250 mL). The solid was air-dried and then dried in vacuo at ambient temperature to a constant weight, giving 109.5 g (98% yield) of the crude product (85.8% ee). The crude solid (55.0 g) and methanol (440 mL) were brought to reflux for 1 hour, cooled to room temperature and stined for an additional 3 hours at ambient temperature. The slurry was filtered and the filter cake was washed with methanol (200 mL). The solid was air-dried and then dried in vacuo at 30 °C to a constant weight, yielding 49.6 g (90% recovery) of (S)-2-(3-ethoxy-4- methoxyphenyl)-l-(methylsulphonyl)-eth-2-ylamine -N-acetyl-L-leucine salt (98.4% ee). Chiral HPLC (1/99 EtOH/20 mM KH2PO4@pH 7.0, Ultron Chiral ES-OVS from Agilent Technologies, 150mm x 4.6 mm, 0.5 mL/min., @240 nm): 18.4 min (S-isomer, 99.2%), 25.5 min (R-isomer, 0.8%). Preparation of Compound A
A 500 mL 3-necked round bottom flask was equipped with a mechanical stiner, thennometer, and condenser. The reaction vessel was charged with (S)-2-(3-ethoxy- 4-methoxyphenyl)-l-(methylsulphonyl)-eth-2-yl amine N-acetyl-L-leucine salt (25 g, 56 mmol, 98% ee), 3 -acetamidophthahc anhydride (12.1 g 58.8 mmol), and glacial acetic acid (250 mL). The mixture was refluxed over night and then cooled to < 50° C. The solvent was removed in vacuo, and the residue was dissolved in ethyl acetate. The resulting solution was washed with water (250 mL x 2), saturated aqeous NaHCO3 (250 mL x 2), brine (250 mL x 2), and dried over sodium sulphate. The solvent was evaporated in vacuo, and the residue recrystallized from a binary solvent containing ethanol (150 mL) and acetone (75 mL). The solid was isolated by vacuum filtration and washed with ethanol (100 mL x 2). The product was dried in vacuo at 60 °C to a constant weight, affording 19.4 g (75% yield) of S-{2-[l-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]- 4-aminoisoindoline-l,3-dione with 98% ee. Chiral HPLC (15/85 EtOH/20 mM KH2PO4 @pH 3.5, Ultron Chiral ES-OVS from Agilent Technology, 150 mm x 4.6 mm, 0.4 mL/min., @240 urn): 25.4 min (S-isomer, 98.7%), 29.5 min (R-isomer, 1.2%). Η-NMR (CDC13) δ:1.47 (t, 3H), 2.26 (s, 3H), 2.87 (s, 3H), 3.68-3.75 (dd, IH), 3.85 (s, 3H), 4.07- 4.15 (q, 2H), 4.51-4.61 (dd, IH), 5.84-5.90 (dd, IH), 6.82-8.77 (m, 6H), 9.46 (s, IH). 13C- NMR (DMSO-d6) δ: 14.66, 24.92, 41.61, 48.53, 54.46, 55.91, 64.51, 111.44, 112.40, 115.10, 118.20, 120.28, 124.94, 129.22, 131.02, 136.09, 137.60, 148.62, 149.74, 167.46, 169.14, 169.48.
5.3. EXAMPLE 3: TNF-α INHIBITION Human Whole Blood LPS-induced TNF-c assay
The ability of compounds to inhibit LPS-induced TNF-α production by human whole blood was measured essentially as described below for the LPS-induced TNF- α assay in human PBMC, except that freshly drawn whole blood was used instead of PBMC. (George Muller, et al. 1999, Bioorganic & Medicinal Chemistry Letters 9; 1625-1630.) Human whole blood LPS-induced TNF-α IC50 - 294 nM
Mouse LPS-induced serum TNF-cc inhibition
Compounds were tested in this animal model according to previously described methods (Corral et al. 1996, Mol. Med 2:506-515). Mouse LPS-induced serum TNF-α inhibition (ED50, mg/kg, p.o.) = 0.05. LPS-induced TNF- production
Lipopolysaccharide (LPS) is an endotoxin produced by gram-negative bacteria such as E. coli which induces production of many pro-inflammatory cytokines, including TNF-α. hi peripheral blood mononuclear cells (PBMC), the TNF-α produced in response to LPS is derived from monocytes, which comprise approximately 5-20% of the total PBMC. Compounds were tested for the ability to inhibit LPS-induced TNF-α production from human PBMC as previously described (Muller et al. 1996, J. Med Chem. 39:3238). PBMC from normal donors were obtained by Ficoll Hypaque (Pharmacia, Piscataway, NJ, USA) density centrifugation. Cells were cultured in RPMI (Life Technologies, Grand Island, NY, USA) supplemented with 10% AB± human serum
(Gemini Bio-products, Woodland, CA, USA), 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ l streptomycin (Life Technologies).
PBMC (2 x 105 cells) were plated in 96-well flat-bottom Costar tissue culture plates (Corning, NY, USA) in triplicate. Cells were stimulated with LPS (Sigma, St. Louis, MO, USA) at 100 ng/ml in the absence or presence of compounds. Compounds (Celgene Corp., Warren, NJ, USA) were dissolved in DMSO (Sigma) and further dilutions were done in culture medium immediately before use. The final DMSO concentration in all samples was 0.25%). Compounds were added to cells 1 hour before LPS stimulation. Cells were incubated for 18-20 hours at 37°C in 5% CO2and supernatants were then collected, diluted with culture medium and assayed for TNF-α levels by ΕLISA (Εndogen, Boston, MA, USA). LPS-induced TNF-α IC50 = 77 nM.
IL-1 β-induced TNF -a production
During the course of inflammatory diseases, TNF-α production is often stimulated by the cytokine IL-1 β, rather than by bacterially derived LPS. Compounds were tested for the ability to inhibit IL-1 β-induced TNF-α production from human PBMC as described above for LPS-induced TNF-α production, except that the PBMC were isolated from source leukocyte units (Sera-Tec Biologicals, North Brunswick, NJ, USA) by centrifugation on Ficoll-Paque Plus (Amersham Pharmacia, Piscataway, NJ, USA), plated in 96-well tissue culture plates at 3 x 105 cells/well in RPMI-1640 medium (BioWhittaker, Walkersville, Maryland, USA) containing 10% heat-inactivated fetal bovine serum (Hyclone), 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (complete medium), pretreated with compounds at 10, 2, 0.4, 0.08, 0.016, 0.0032, 0.00064, and 0 μM in duplicate at a final DMSO concenfration of 0.1% at 37°C in a humidified incubator at 5% CO2 for 1 hour, then stimulated with 50 ng/ml recombinant human IL-lβ (Endogen) for 18 hours. IL-β-induced TNF-α IC50 = 83 nM.
5.4. EXAMPLE 4: PDE SELECTIVITY
PDEl, 2, 3, 5, and 6 enzyme assays
The specificity of compounds for PDE4 was assessed by testing at a single concentration (10 μM) against bovine PDEl, human PDE2, PDE3, and PDE5 from human platelets (Hidaka and Asano 1976, Biochem. Biophys. Acta 429:485, and Nicholsen et al. 1991, Trends Pharmaco. Sci. 12:19), and PDE6 from bovine retinal rod outer segments (Baehr et al. 1979, J. Biol. Chem. 254:11669, and Gillespie et al. 1989, Mol. Pharm. 36:773). Results are listed in Table 1.
PDEl enzyme assay
PDE7 is a cAMP-selective PDE expressed mainly in T cells and in skeletal muscle. T cell-derived cytokines such as IL-2 and IFN-γ are potentially regulatable via PDE7 inhibition. PDE7 was purified from Hut78 human T cells by anion exchange chromatography as previously described (Bloom and Beavo 1996, Proc. Natl. Acad Sci. USA 93:14188-14192). Compounds were tested against the PDE7 preparation in the presence of 10 nM cAMP as described for PDE4 in Table 1 below.
Table 1.
Figure imgf000032_0001
Figure imgf000033_0001
*Compound B is the opposite enantiomer of Compound A.
5.5. EXAMPLE 5: PDE4 INHIBITION
PDE4 (U937 cell-derived) enzyme assay
PDE4 enzyme was purified from U937 human monocytic cells by gel filtration chromatography as previously described (MuUer et al. 1998, Bioorg. & Med Chem Lett 8:2669-2674). Phosphodiesterase reactions were carried out in 50 mM Tris HCl pH 7.5, 5 mM MgCl2, 1 μM cAMP, 10 nM [3H]-cAMP for 30 min at 30°C, terminated by boiling, treated with 1 mg/ml snake venom, and separated using AG-1XS ion exchange resin (BioRad) as described (Muller et al. 1998, Bioorg. &Med Chem Lett 8:2669-267 '4). Reactions consumed less than 15% of available substrate. Results are listed in Table 1.
5.6. EXAMPLE 6: HUMAN T CELL ASSAYS
SEE -induced IL-2 and IFN- γ production
Staphylococcal Εnterotoxin B (SΕB) is a superantigen derived from gram- positive bacteria Staphylococcus aureus. SΕB provides a convenient physiological stimulus specific for T cells expressing particular T cell receptor Vβ chains. Human PBMC (consisting of approximately 50% T cells) were isolated from source leukocyte units as described above and plated in 96-well tissue culture plates at 3 x 105 cells/well in complete medium, prefreated with compounds at 10, 2, 0.4, 0.08, 0.016, 0.0032, 0.00064, and 0 μM in duplicate at a final DMSO concentration of 0.1 % at 37°C in a humidified incubator at 5% CO2for 1 hour, then stimulated with 100 ng/ml SΕB (Sigma Chemical Co., St. Louis, MO, USA) for 18 hours. IL-2 and IFN-γ levels were measured by ELISA (R&D Systems, Minneapolis, MN, USA). IL-2 IC50 = 291 nM. IFN-γ IC50 = 46 nM.
5.7. EXAMPLE 6: cAMP ELEVATION ASSAYS PGE2-induced cAMP elevation
Prostaglandin E2 (PGE2) binds to prostanoid receptors on monocytes, T cells and other leukocytes and consequently elevates intracellular cAMP levels, resulting in inhibition of cellular responses. The combination of PGE2and a PDE4 inhibitor synergistically elevates cAMP levels in these cell types, and the elevation of cAMP in PBMC caused by PDE4 inhibitors in the presence of PGE2 is proportional to the inhibitory activity of that PDE4 inhibitor. Intracellular cAMP was measured in human PBMC as follows. PBMC were isolated as described above and plated in 96-well plates at 1 x 106 cells per well in RPMI-1640. The cells were pre-treated with compounds at 100, 10, 1, 0.1, 0.01, and 0 μM in a final concentration of 2% DMSO in duplicate at 37°C in a humidified incubator at 5% CO2 for one hour. The cells were then stimulated with PGE2 (1 OμM) (Sigma) for lh. The cells were lysed with HCl, 0.1N final concentration to inhibit phosphodiesterase activity and the plates were frozen at -20°C. The cAMP produced was measured using cAMP (low pH) hnmunoassay kit (R&D Systems). PBMC cAMP EC50 for racemate is 3.09μM. PBMC cAMP EC50 for Compound A is 1.58 μM. Elevation of cAMP in human neufrophils was measured as follows. PBMC were removed from source leukocytes (Sera-Tec Biologicals) by centrifugation on Ficoll— Paque Plus (Amersham Pharmacia). The resulting erythrocyte/polymorphonuclear cell (PMN) pellet was resuspended in Hank's Balanced Salt Solution (BioWhittaker) and mixed with an equal volume of 3% Dextran T-500 (Amersham Pharmacia) in 0.9% saline. Erythrocytes were allowed to sediment for 20 minutes, and the PMN were removed and centrifuged at 120 rpm for 8 minutes at 4°C. The remaining erythrocytes were lysed in cold 0.2% saline for 30 seconds, and the cells restored to isotonicity by the addition of an equal volume of 1.6% saline. The PMN were centrifuged at 1200 rpm for 8 minutes at 4°C, then resuspended in RPMI-1640 and assayed for cAMP elevation as described for PBMC above. PMN were found to be approximately 74% CD18/CD1 lb+, 71% CD16+CD9+ neufrophils by flow cytometzy on a FACSCalibur (Becton Dickinson, San Jose, CA, USA). Results are shown in Table 2. fMLF-induced LTB4 production
N-formyl-methionine-leucine-phenylalanine (fMLF) is a bacterially derived peptide that activates neufrophils to rapidly degranulate, migrate, adhere to endothelial cells, and release leukotriene LTB4, a product of arachidonic acid metabolism and itself a neufrophil chemoatfractant. Compounds were tested for the ability to block fMLF-induced neufrophil LTB4 production as previously described (Hatzelmann and Schudt 2001, J. Pharm. Exp. Ther. 297:267-279), with the following modifications. Neufrophils were isolated as described above and resuspended in phosphate-buffered saline without calcium or magnesium (BioWhittaker) containing 10 mM HEPES pH7.2 and plated in 96-well tissue culture plates at a concenfration of 1.7 x 106 cells/well. Cells were treated with 50 μM thimerosal (SigmaVl mM CaCl2/l mM MgCl2 for 15 minutes at 37°C 5% CO2, then treated with compounds at 1000, 200, 40, 8, 1.6, 0.32, 0.064, and 0 nM in a final DMSO concentration of 0.01% in duplicate for 10 minutes. Neufrophils were stimulated with 1 μM fMLF for 30 minutes, then lysed by the addition of methanol (20% final concentration) and frozen in a dry ice/isopropanol bath for 10 minutes. Lysates were stored at -70°C until the LTB4 content was measured by competitive LTB4 ELISA (R&D Systems). Results are shown in Table 2.
Zymosan-induced IL-8 production Zymosan A, or the heat-killed yeast Saccharomyces cerevisiae, binds to the adhesion molecule Mac-1 on the neufrophil surface and triggers phagocytosis, cell activation and IL-8 production. Zymosan-induced IL-8 production was measured as previously described (Au et al. 1998, Brit. J. Pharm. 123:1260-1266) with the following modifications. Human neufrophils were purified as described above, plated in 96-well tissue culture plates at 3xl05 cells/well in complete medium, treated with compounds at 10, 2, 0.4, 0.08, 0.016, 0.0032, 0.00064, and 0 μM in duplicate in a final DMSO concentration of 0.1% for 1 hour at 37°C 5%CO2. Neufrophils were then stimulated with unopsonized, boiled Zymosan A (Sigma) at 2.5 x 105 particles/well for 18 hours. Supernatants were harvested and tested for IL-8 by ELISA (R&D Systems). Results are shown in Table 2.
fMLF-induced CDI8/CDllb expression
CD18/CD1 lb (Mac-1) expression on neufrophils was measured as previously described (Derian et al. 1995, J. Immunol: 154:308-3 17) with the following modifications. Neufrophils were isolated as described above, then resuspended in complete medium at lxlO6 cells/ml, pretreated with compounds at 10, 1, 0.1, 0.01, and 0 μM in duplicate at a final DMSO concentration of 0.1% for 10 minutes at 37°C 5%CO2. Cells were then stimulated with 30 nM fMLF for 30 minutes and then chilled to 4°C. Cells were treated with rabbit IgG (Jackson J-mmxmoResearch Labs, West Grove, PA, USA) (10 μg/lxl06 cells) to block Fc receptors, stained with CD18-FITC and CDllb-PE (Becton Dickinson), and analyzed by flow cytometry on a FACSCalibur. CD 18/CD l ib expression (mean fluorescence) in the absence of stimulation was subtracted from all samples to obtain inhibition curves and calculate IC50s. Results are shown in Table 2.
fMLF-induced adhesion to HUVEC Human umbilical vein endothelial cells (HUVEC) were used as a substrate for neufrophil adhesion as previously described (Derian et al. 1995, J. Immunol: 154:308- 317) with the following modifications. HUVEC cells were obtained from Anthrogenesis (Cedar Knolls, NJ, USA), and neufrophils were not treated with cytochalasin B. Cells were treated with compounds at 10, 1, 0.1, 0.01, 0.001, and 0 μM in a final DMSO concentration of 0.1% in duplicate for 10 minutes, stimulated with 500 nM fMLF for 30 minutes, and washed twice with PBS before measuring fluorescence on an FLX800 plate reader (Bio-Tek Instruments, Winooski, VT, USA). Results are shown in Table 2.
Table 2.
Figure imgf000036_0001
5.8. EXAMPLE 8: AQUEOUS SOLUBILITY
Equilibrium solubilities were measured in pH 7.4 aqueous buffer. The pH 7.4 buffer was prepared by adjusting the pH of a 0.07 M NaH2PO4 solution to 7.4 with IO N NaOH. The ionic strength of the solution was 0.15. At least 1 mg of powder was combined with 1 ml of buffer to make >1 mg/ml mixture. These samples were shaken for >2 hours and left to stand overnight at room temperature. The samples were then filtered through a 0.45-μm Nylon syringe filter that was first saturated with the sample. The filtrate was sampled twice, consecutively. The filtrate was assayed by HPLC against standards prepared in 50% methanol. Compound A has 3.5 -fold greater aqueous solubility than the racemic mixture. Measured solubility Compound A = 0.012 mg/mL; racemic mixture = 0.0034mg/mL.
5.9. EXAMPLE 8: LPS-INDUCED LUNG NEUTROPHILIA FERRET MODEL The conscious fenet model has been used to investigate anti-inflammatory, emetic and behavioral effects of PDE4 inhibitors when administered by the oral (p.o.) route. From these experiments, a therapeutic index (TI) for each PDE4 inhibitor may be determined. The TI has been calculated by dividing the threshold dose for causing emetic episodes and behavioral changes by the anti-inflammatory dose (dose that causes 50% inhibition of the LPS-induced neutrophilia).
Animal husbandry
Male fenets (Mustela Pulorius Euro, weighing 1 - 2 kg). Fercets were supplied either by Bury Green Farm or Misay Consultancy. Following transport, the animals were allowed to acclimatize in the holding rooms for a period of not less than 7 days. The Diet comprised SDS diet C pelleted food given ad lib with Whiskers cat food given 3 times per week. Water was pasteurized animal grade drinking water and was changed daily.
Dosing with PDE4 inhibitor PDE4 inhibitors were administered orally (p.o.), at doses initially of 1-10 mg/kg, but subsequently up to 30 mg/kg in order to establish whether the TI was 10 or higher, and/or at lower doses to establish the minimum dose to cause 50% inhibition of neutrophilia. Ferrets were fasted overnight but allowed free access to water. The animals were orally dosed with vehicle or PDE4 inhibitor using a 15cm dosing needle that was passed down the back of the throat into the oesophagus. After dosing, the animals were returned to holding cages fitted with Perspex doors to allow observation, and given free access to water. After dosing, the animals were constantly observed and any emesis or behavioural changes were recorded. The animals were allowed access to food 60 - 90 minutes after p.o. dosing Exposure to LPS
Thirty minutes after p.o. dosing with compound or vehicle control, the ferrets were placed into sealed Perspex containers and exposed to an aerosol of LPS (100 μg/ml) for 10 minutes. Aerosols of LPS were generated by a nebulizer (DeVilbiss, USA) and this was directed into the Perspex exposure chamber. Following a 10 minute exposure period, the animals were returned to the holding cages and allowed free access to water, and at a later stage, food. Observation continued for a period of at least 2.5 hours post p.o. dosing and emetic episodes and behavioral changes were recorded.
Bronchoalveolar lavage
Six hours after LPS exposure the animals were killed by overdose of sodium pentobarbitone administered intraperitoneally. The trachea was then cannulated with polypropylene tubing and the lungs lavaged twice with 20 ml heparinized (10 units/ml) phosphate buffered saline (PBS).
Blood sampling / tissue removal
A terminal blood sample (10 ml) was removed by trans-thoracic cardiac puncture. The blood was spun at 2500rpm for 15 minutes and the plasma removed and stored at -20°C. The brain also removed and frozen at -20°C for analysis of compound content.
Cell counts
The bronchoalveolar lavage (BAL) samples were centrifuged at 1500 rpm for 5 minutes. The supernatant was removed and the resulting cell pellet re-suspended in 1 ml PBS. A cell smear of the re-suspended fluid was prepared and stained with Leishmans stain to allow differential cell counting. A total cell count was made using the remaining resuspended sample. From this, the total number of neufrophils in the BAL was determined.
Parameters measured: 1. % Inhibition of LPS-induced pulmonary neutrophilia.
2. Emetic episodes - the number of vomits and retches were counted.
3. Behavioral changes - the following behavioral effects were noted: salivation, panting, mouth clawing, flattened posture, ataxia, arched back and backward walking. Any behavioral changes were semi-quantified by applying a severity rating (mild, moderate or severe). 4. The TI was calculated as the highest dose found to not cause emetic episodes divided by the lowest dose found to inhibit pulmonary neutrophilia by 50% or more.
The effect of Compound A on LPS-induced neutrophilia in the lungs of conscious fenets is demonstrated in Figure 1.
Emesis and behavioral changes
Following p.o. dosing of the PDE4, the ferrets were observed for at least 2 hours and emetic episodes (vomits and retches) and behavioral changes were recorded. No emetic episodes (retching or vomiting) were observed in the fenets pre- treated p.o. with the relevant vehicle (acetone/cremophor /distilled water), hi a small proportion of the control-treated animals (7/22), mild behavioral changes (lip licking and backward walking) were seen.
Compound A (0.1 -3 mg/kg, p.o.), caused no emetic episodes (retching and vomiting). Some behavioral changes (flattened posture, lip licking and backward walking) were observed and classified as mild. At 10 mg/kg in 2/6 ferrets, some retching but no frank emesis was observed along with salivation and behavioral changes (scored as mild or moderate). At the highest dose tested (30mg/kg) moderate to marked emesis was observed in 3/4 animals along with pronounced behavioral changes. These data are summarized in Table m.
Table III. Conscious ferret: Emetic episodes and behavioural changes following oral administration of Compound A.
Figure imgf000039_0001
Animals were observed for up to 3 hours following dosing. Numbers in parentheses refer to the number of animals that responded The numbers of animals in each group range from 4-22.
Therapeutic Index Calculation
From these experiments, a therapeutic index (TI) was determined for each compound by dividing the threshold dose for inducing emetic episodes by the ED50 value for inhibiting the pulmonary neutrophilia. The TI calculation is summarized in Table IV. Compoimd A had a TI of 12, causing no emetic episodes at an anti-inflammatory dose of 1 mg/kg.
Table IV. Summary of the effective doses (ED 5^ for inhibition of LPS-induced pulmonary neutrophilia and induction of emesis and the therapeutic index derived from these values.
Figure imgf000040_0001
5.10. EXAMPLE 9: 200 MG DOSAGE CAPSULE Table V illustrates a batch formulation and single dosage formulation for a 200 mg
Compound A single dose unit, i.e., about 40 percent by weight, in a size #0 capsule.
Table V. Formulation for 200 mg capsule
Figure imgf000040_0002
The pregelatinized corn starch (SPRESS B-820) and Compound A components are passed through a 710 μ m screen and then are loaded into a Diffusion Mixer with a baffle insert and blended for 15 minutes. The magnesium stearate is passed through a 210 μ m screen and is added to the Diffusion Mixer. The blend is then encapsulated in a size #0 capsule, 500 mg per capsule (8400 capsule batch size) using a Dosator type capsule filling machine.
5.11. EXAMPLE 10: 100 MG ORAL DOSAGE FORM
Table VI illustrates a batch formulation and a single dose unit formulation containing 100 mg of Compound A.
Table VI. Formulation for 100 mg tablet
Figure imgf000041_0001
The microcrystalline cellulose, croscarmellose sodium, and Compound A components are passed through a #30 mesh screen (about 430μ to about 655μ). The Pluronic F-68® (manufactured by JRH Biosciences, Inc. of Lenexa, KS) surfactant is passed through a #20 mesh screen (about 457μ to about 1041 μ). The Pluronic F-68® surfactant and 0.5 kgs of croscarmellose sodium are loaded into a 16 qt. twin shell tumble blender and are mixed for about 5 minutes. The mix is then transferred to a 3 cubic foot twin shell tumble blender where the microcrystalline cellulose is added and blended for about 5 minutes. The thalidomide is added and blended for an additional 25 minutes. This pre-blend is passed through a roller compactor with a hammer mill attached at the discharge of the roller compactor and moved back to the tumble blender. The remaining croscarmellose sodium and magnesium stearate is added to the tumble blender and blended for about 3 minutes. The final mixture is compressed on a rotary tablet press with 250 mg per tablet (200,000 tablet batch size).
5.12. EXAMPLE 11: AEROSOL DOSAGE FORM
A concentrate is prepared by combining Compound A, and a 12.6 kg portion of the trichloromonofluoromethane in a sealed stainless steel vessel equipped with a high shear mixer. Mixing is carried out for about 20 minutes. The bulk suspension is then prepared in the sealed vessel by combining the concentrate with the balance of the propellants in a bulk product tank that is temperature controlled to 21° to 27 °C. and pressure controlled to 2.8 to 4.0 BAR. 17 ml aerosol containers which have a metered valve which is designed to provide 100 inhalations of the composition of the invention. Each container is provided with the following:
Compound A 0.0120 g trichloromonofluoromethane 1.6939 g dichlorodifluoromethane 3.7175g dichlorotetrafluoroethane 1.5766 g total 7.0000 g
While the invention has been described with respect to the particular embodiments, it will be apparent to those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the mvention as defined in the claims. Such modifications are also intended to fall within the scope of the appended claims.

Claims

THE CLAIMSWhat is claimed is:
1. A method of inhibiting TNF-α production which comprises contacting a cell which produces TNF-α with an effective amount of stereomerically pure (+)-2-[l-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline- 1,3-dione, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
2. A method of inhibiting PDE4 activity which comprises contacting PDE4 with an effective amount of stereomerically pure (+)-2-[l-(3-Ethoxy-4- methoxvphenyl)-2-methylsulfonylethyl]-4-acetylaminoisomdoline- 1 ,3-dione, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
3. The method of claim 1 or 2 wherein the contact is in a mammalian cell.
4. The method of claim 3 wherein the cell is human.
5. A method of treating or preventing diseases or disorders ameliorated by reduction of levels of TNF-α in a patient which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of stereomerically pure (+)-2-[l -(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline-l,3-dione, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
6. A method of treating or preventing cancer which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of stereomerically pure (+)-2-[l-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline- 1 ,3-dione, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
7. The method of claim 5 or 6 further comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of an alkylating agent, nitrogen mustard, a JNK inhibitor, antibiotic, antineoplastic agent, ethylenimine, methyhnelamine alkyl sulfonate, nitrosourea, triazene, folic acid analog, pyrimidine analog, purine analog, vinca alkaloid, epipodophyllotoxin, a topoisomerase inhibitor, or an anti-cancer vaccine.
8. The method of claim 6 wherein the cancer is a solid tumor.
9. The method of claims 6 wherein the cancer is a blood-born tumor.
10. The method of claim 6 wherein the cancer is multiple myeloma, acute leukemia, lymphoblastic leukemia, myelogenous leukemia, lymphocytic leukemia, or myelocytic leukemia.
11. The method of claim 8 wherein the solid tumor is a tumor of the breast, colon, rectum, colorectum, kidney, or a glioma.
12. The method of claim 5 or 6 wherein the patient is a mammal.
13. The method of claim 5 or 6 wherein the stereomerically pure (+)-2- [l-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione is administered parenterally, transdermally, mucosally, nasally, buccally, sublingually, or orally.
14. The method of claim 13 wherein the stereomerically pure (+)-2-[ 1 -(3 - Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione is administered orally.
15. The method of claim 14 wherein the stereomerically pure (+)-2-[l-(3-
Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione is administered orally in a tablet or capsule form.
16. The method of claim 15 wherein the therapeutically or prophylactively effective amount is from about 1 mg to about 1000 mg per day.
17. The method of claim 16 wherein the therapeutically or prophylactively effective amount is from about 5 mg to about 500 mg per day.
18. The method of claim 17 wherein the therapeutically or prophylactively effective amount is from about 10 mg to about 200 mg per day.
19. A method of treating or preventing diseases or disorders ameliorated by the inhibition of PDE4 in a patient which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of stereomerically pure (+)-2-[l-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline-l,3-dione, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
20. A method of treating or preventing depression, asthma, inflammation, inflammatory skin disease, psoriasis, atopic dermatitis, contact dermatitis, rheumatoid arthritis, osteoarthritis, chronic obstructive pulmonary disease, chronic pulmonary inflammatory disease, inflammatory bowel disease, Crohn's Disease, Bechet's Disease or colitis which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of stereomerically pure (+)-2-[l-(3- Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione, or a phannaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clatlirate thereof.
21. A method of controlling cAMP levels in a cell which comprises contacting a cell with an effective amount of stereomerically pure (-)-2-[ 1 -(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
22. A method of treating or preventing MDS in a patient which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of stereomerically pure (+)-2-[l-(3- Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
23. A method of treating or preventing MPD in a patient which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of stereomerically pure (+)-2-[l-(3- Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
24. A method of treating or preventing complex regional pain syndrome in a patient which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of stereomerically pure (+)-2- [ 1 -(3 -Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl] -4-acetylaminoisoindoline- 1,3-dione, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
25. The method of claim 19 or 20 further comprising administering to a patient in need of such freatment or prevention a therapeutically or prophylactically effective amount of an antihistamine, anti-inflammatory drug, non-steroid anti- inflammatory drug, or steroid.
26. The method of claim 19 wherein the disease or disorder is asthma, allergic rhinitis, inflammation, or chronic pulmonary inflammatory disease.
27. The method of claim 19 wherein the disease or disorder is chronic obstructive pulmonary disease.
28. The method of claim 19 or 20 wherein the patient is a mammal.
29. The method of claim 19 or 20 wherein the stereomerically pure (+)-2- [ 1 -(3 -Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl] -4-acetylaminoisoindoline- 1 ,3-dione is administered parenterally, fransdermally, mucosally, nasally, buccally, sublingually, or orally.
30. The method of claim 29 wherein the stereomerically pure (+)-2-[ 1 -(3 - Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione is administered orally.
31. The method of claim 30 wherein the stereomerically pure (+)-2-[ 1 -(3- Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl] -4-acetylaminoisoindoline- 1 ,3 -dione is administered orally in a tablet or capsule form.
32. The method of claim 19 or 20 wherein the therapeutically or prophylactively effective amount is from about 1 mg to about 1000 mg per day.
33. The method of claim 32 wherein the therapeutically or prophylactively effective amount is from about 5 mg to about 500 mg per day.
34. The method of claim 33 wherein the therapeutically or prophylactively effective amount is from about 10 mg to about 200 mg per day.
35. A pharmaceutical composition comprising stereomerically pure (+)- 2- [ 1 -(3 -Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl] -4-acetylaminoisoindoline- 1,3- dione, or a pharmaceutically acceptable polymorph, prodrug, salt, solvate, hydrate, or clathrate thereof; and a pharmaceutically acceptable carrier, excipient or diluent.
36. The pharmaceutical composition of claim 35 wherein said pharmaceutical composition is suitable for parenteral, fransdermal, mucosal, nasal, buccal, sublingual, or oral administration to a patient.
37. The pharmaceutical composition of claim 36 wherein said pharmaceutical composition is suitable for oral administration to a patient.
38. The pharmaceutical composition of claim 30 wherein the amount of stereomerically pure (+)-2-[l-(3-Ethoxy-4-methoxyphenyl)-2- methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione is from 1 mg to 1000 mg.
39. The pharmaceutical composition of claim 38 wherein the amount of stereomerically pure (+)-2-[ 1 -(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline-l,3-dione is from 5 mg to 500 mg.
40. The pharmaceutical composition of claim 39 wherein the amount of stereomerically pure (+)-2- [ 1 -(3 -Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl] -4- acetylaminoisoindoline-l,3-dione is from 10 mg to 200 mg.
41. A single unit dosage form which comprises a stereomerically pure
(+)-2-[l-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline- 1,3 -dione or a phannaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof; and a pharmaceutically acceptable carrier, excipient or diluent.
42. The dosage form of claim 41 wherein said dosage fonn is suitable for parenteral, transdermal, mucosal, nasal, buccal, sublingual, or oral administration to a patient.
43. The dosage form of claim 42 wherein said dosage form is a capsule or a tablet.
44. The dosage form of claim 43 wherein said dosage form is an aerosol.
45. The dosage form of claim 41 wherein the amount of stereomerically pure (+)-2-[ 1 -(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline- 1,3 -dione is from about 1 mg to about 1000 mg.
46. The dosage form of claim 45 wherein the amount of stereomerically pure (+)-2-[ 1 -(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline-l,3-dione is from about 5 mg to about 500 mg.
47. The dosage form of claim 46 wherein the amount of stereomerically pure (+)-2-[ 1 -(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline-l,3-dione is from about 10 mg to about 200 mg.
48. Stereomerically pure (+)-2-[ 1 -(3 -Ethoxy-4-methoxyphenyl)-2- methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione, substantially free of its (-) isomer, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate, hydrate, or clathrate thereof.
49. A method of producing a stereomerically pure enantiomer of 2-[l-(3- Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione which comprises:
(a) contacting 1 -(3 -Ethoxy-4-methoxy-phenyl)-2-methanesulfonyl- ethylamine with a chiral amino acid under a condition sufficient to form a chiral amino acid salt of l-(3-Ethoxy-4-methoxy-phenyl)-2-methanesulfonyl- ethylamine ; and
(b) contacting the chiral amino acid salt of
1 -(3 -Ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethylamine with N-(l,3-Dioxo-l,3-dihydro-isobenzofuran-4-yl)-acetamide under a condition sufficient to form a final product..
50. The method of claim 49 wherein the chiral amino acid is the L isomer of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosme, valine, ornithine, 4-aminobutyric acid, 2-amino isobutyric acid, 3- amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citruUine, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, or N-acetyl- leucine.
51. The method of claim 50 wherein the chiral amino acid is N-acetyl-L- leucine.
52. A stereomerically pure salt of (S)-2-(3-ethoxy-4-methoxyphenyl)- 1 - (methylsulphonyl)-eth-2-ylamine.
53. The stereomerically pure salt of claim 52 which is chiral amino acid salt.
54. The stereomerically pure salt of claim 53 wherein the a salt of the L isomer of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, ornithine, 4-aminobutyric acid, 2-amino isobutyric acid, 3 -amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citruUine, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, or N-acetyl-leucine.
55. The stereomerically pure salt of claim 54 which is a (S)-2-(3-ethoxy- 4-methoxyphenyl)-l-(methylsulphonyl)-eth-2-ylamine N-acetyl-L-leucine salt.
PCT/US2003/008738 2002-03-20 2003-03-20 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof WO2003080049A1 (en)

Priority Applications (30)

Application Number Priority Date Filing Date Title
JP2003577877A JP2005525386A (en) 2002-03-20 2003-03-20 (+)-2- [1- (3-Ethoxy-4-methoxyphenyl) -2-methylsulfonylethyl] -4-acetylaminoisoindoline-1,3-dione, methods of use and compositions thereof
KR1020127000230A KR101263786B1 (en) 2002-03-20 2003-03-20 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione： methods of using and compositions thereof
KR1020137021411A KR20130100219A (en) 2002-03-20 2003-03-20 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
EP10162667.9A EP2223688B1 (en) 2002-03-20 2003-03-20 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of Using and Compositions Thereof
SI200331659T SI1485087T1 (en) 2002-03-20 2003-03-20 (+)-2- ?á1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL?å-4-ACETYLAMINOISOINDOLINE-1,3-DIONE FOR USE IN TREATING PSORIASIS BY ORAL ADMINISTRATION
AT03721414T ATE440599T1 (en) 2002-03-20 2003-03-20 (+)-2-Ä1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYLÜ-4-ACETYLAMINOISOINDOLIN-1, -DIONE FOR USE IN THE TREATMENT OF PSORIASIS BY ORAL ADMINISTRATION
KR1020137004997A KR101383845B1 (en) 2002-03-20 2003-03-20 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione： methods of using and compositions thereof
EP15177140.9A EP2962690B1 (en) 2002-03-20 2003-03-20 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
AU2003224729A AU2003224729C9 (en) 2002-03-20 2003-03-20 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
EP19151685.5A EP3524242A1 (en) 2002-03-20 2003-03-20 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
EP03721414A EP1485087B1 (en) 2002-03-20 2003-03-20 (+)-2- [1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione for use in treating psoriasis by oral administration
NZ535798A NZ535798A (en) 2002-03-20 2003-03-20 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
KR1020107003988A KR101104991B1 (en) 2002-03-20 2003-03-20 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
KR1020047015190A KR100997001B1 (en) 2002-03-20 2003-03-20 + -2- [1- 3-ethoxy-4-methoxyphenyl- 2-methylsulfonylethyl]-4-acetylaminoisoindoline-1, 3-dione: methods of using and compositions thereof
IL16414703A IL164147A0 (en) 2002-03-20 2003-03-20 (+)-2-Ä1-(3-Ethoxy-4-methoxyphenyl)-2methylsulfonylethylÜ-4-acetylaminoisoindoline-1,3-dione:methodsof using and compositions thereof
DK03721414T DK1485087T3 (en) 2002-03-20 2003-03-20 (+) - 2 [1- (3-Ethoxy-4-methoxyphenyl) -2-methylsulfonylethyl] -4-acetylaminoisoindoline-1,3-dione for use in the treatment of psoriasis by oral administration
DE60328974T DE60328974D1 (en) 2002-03-20 2003-03-20 (+) - 2-Ä1- (3-ETHOXY-4-METHOXYPHENYL) -2-METHYLSULFONYLETHYLÜ-4-ACETYLAMINOISOINDOLIN-1,3-DION FOR USE IN THE TREATMENT OF PSORIASIS BY ORAL ADMINISTRATION
MXPA04009075A MXPA04009075A (en) 2002-03-20 2003-03-20 (+)-2- [1-(3-ethoxy -4-methoxyphenyl) -2- methylsulfonylethyl]- 4- acetylaminoisoindoline-1, 3-dione: methods of using and compositions thereof.
CA2479666A CA2479666C (en) 2002-03-20 2003-03-20 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
MX2015010082A MX366328B (en) 2002-03-20 2003-03-20 (+)-2- [1-(3-ethoxy -4-methoxyphenyl) -2- methylsulfonylethyl]- 4- acetylaminoisoindoline-1, 3-dione: methods of using and compositions thereof.
IL164147A IL164147A (en) 2002-03-20 2004-09-20 Stereomerically pure salt of (s) - 2 - (3 - ethoxy - 4 - methoxyphenyl) - 1- (methylsulfonylethy)] - eth - 2 - ylamine, process for its manufacture and pharmaceutical compositions comprising it for treating diseases
HK05104139.9A HK1073426A1 (en) 2002-03-20 2005-05-17 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminois oindoline-1, 3-dione for use in treating psoriasis by oral administration
IL207149A IL207149A (en) 2002-03-20 2010-07-22 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutical acceptable polymorph, salt, solvate or hydrate thereof for use in treating an autoimmune disease, optionally in combination with an anti-inflammatory drug
CY20191100372T CY1121720T1 (en) 2002-03-20 2019-04-03 (+) - 2- [1- (3-ETHOXY-4-METHOXYPHENYL) -2-METHYLSULPHONYLAETHYL] -4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USE AND USE
LU00125C LUC00125I2 (en) 2002-03-20 2019-06-14
BE2019C008C BE2019C008I2 (en) 2002-03-20 2019-06-18
CY2019032C CY2019032I2 (en) 2002-03-20 2019-06-18 (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULPHONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USE AND COMPOSITIONS THEREOF
NL300994C NL300994I2 (en) 2002-03-20 2019-06-18 Apremilast or a pharmaceutically acceptable salt thereof
FR19C1046C FR19C1046I2 (en) 2002-03-20 2019-07-12 (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULPHONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USE AND COMPOSITIONS THEREOF
CY20191100877T CY1121888T1 (en) 2002-03-20 2019-08-14 (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLOSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USE AND COMPOSITIONS THEREOF

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36651502P 2002-03-20 2002-03-20
US60/366,515 2002-03-20
US43845003P 2003-01-07 2003-01-07
US60/438,450 2003-01-07

Publications (1)

Publication Number Publication Date
WO2003080049A1 true WO2003080049A1 (en) 2003-10-02

Family

ID=28457137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/008738 WO2003080049A1 (en) 2002-03-20 2003-03-20 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof

Country Status (24)

Country Link
US (14) US6962940B2 (en)
EP (9) EP2295055B1 (en)
JP (4) JP2005525386A (en)
KR (6) KR101263786B1 (en)
CN (2) CN101683334A (en)
AT (1) ATE440599T1 (en)
AU (1) AU2003224729C9 (en)
BE (1) BE2019C008I2 (en)
CA (2) CA2756798A1 (en)
CY (6) CY1109380T1 (en)
DE (1) DE60328974D1 (en)
DK (6) DK2223687T3 (en)
ES (8) ES2608495T3 (en)
FR (1) FR19C1046I2 (en)
HK (3) HK1073426A1 (en)
HU (5) HUE034348T2 (en)
IL (3) IL164147A0 (en)
LU (1) LUC00125I2 (en)
MX (2) MXPA04009075A (en)
NL (1) NL300994I2 (en)
NZ (1) NZ535798A (en)
PT (6) PT2962690T (en)
SI (5) SI2223687T1 (en)
WO (1) WO2003080049A1 (en)

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087148A1 (en) * 2003-03-31 2004-10-14 Kyowa Hakko Kogyo Co. Ltd. Remedy and/or preventive for lung diseases
WO2005056009A1 (en) * 2003-12-12 2005-06-23 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for lung disease
EP1569903A2 (en) * 2002-11-06 2005-09-07 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
WO2005107725A1 (en) * 2004-05-06 2005-11-17 Biolipox Ab Use of ltb4 inhibitors for the treatment of b-cell leukemias and lymphomas
WO2005108353A2 (en) * 2004-05-06 2005-11-17 Ceptor Corporation Compounds for treating neurologic diseases, otologic diseases, or ophthalmologic diseases and methods of use thereof
US7019030B2 (en) 1996-08-12 2006-03-28 Celgene Corporation Immunotherapeutic agents
WO2006065814A1 (en) * 2004-12-13 2006-06-22 Celgene Corporation Compositions comprising pde4 modulators and their use for the treatment or prevention of airway inflammation
EP1679967A2 (en) * 2003-10-23 2006-07-19 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drus for treatment, modification and management of pain
EP1744748A2 (en) * 2004-04-14 2007-01-24 Celgene Corporation Method of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myelodysplastic syndromes
EP1746989A1 (en) * 2004-05-05 2007-01-31 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
WO2007079182A1 (en) * 2005-12-29 2007-07-12 Celgene Corporation Methods for treating cutaneous lupus using aminoisoindoline compounds
JP2007524656A (en) * 2003-10-23 2007-08-30 セルジーン・コーポレーション Compositions comprising selective cytokine inhibitors for treating, modifying and managing pain and methods of use thereof
JP2008544993A (en) * 2005-06-30 2008-12-11 セルジーン・コーポレーション Process for preparing 4-amino-2- (2,6-dioxopiperidin-3-yl) isoindoline-1,3-dione compound
EP2036553A1 (en) * 2002-10-24 2009-03-18 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
WO2009120167A1 (en) * 2008-03-27 2009-10-01 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7776907B2 (en) 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
WO2010093588A1 (en) 2009-02-10 2010-08-19 Celgene Corporation Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US20110124702A1 (en) * 2009-11-10 2011-05-26 Chen Ming J Nanosuspension of a Poorly Soluble Drug via Microfluidization Process
WO2011127019A2 (en) 2010-04-07 2011-10-13 Celgene Corporation Methods for treating respiratory viral infection
WO2011159750A1 (en) 2010-06-15 2011-12-22 Celgene Corporation Biomarkers for the treatment of psoriasis
WO2012096884A1 (en) * 2011-01-10 2012-07-19 Celgene Corporation Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
CN102898349A (en) * 2008-03-27 2013-01-30 细胞基因公司 Solid containing compound, a composition containing the solid and use of the solid
EP2687213A1 (en) * 2008-03-27 2014-01-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US8952178B2 (en) 2009-05-14 2015-02-10 Tianjin Hemay Bio-Tech Co., Ltd. Thiophene derivatives
WO2015112568A1 (en) 2014-01-24 2015-07-30 Celgene Corporation Methods for the treatment of obesity using apremilast
WO2015175956A1 (en) 2014-05-16 2015-11-19 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
WO2015173792A1 (en) 2014-05-11 2015-11-19 Mapi Pharma Ltd. Amorphous form of apremilast
EP2949645A1 (en) 2014-05-28 2015-12-02 LEK Pharmaceuticals d.d. Processes for the preparation of ß-aminosulfone compounds
WO2015200177A1 (en) 2014-06-23 2015-12-30 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
WO2016016824A1 (en) 2014-07-29 2016-02-04 Fundacio Hospital Universitari Vall D' Hebron-Institut De Recerca Differential diagnosis and therapy selection for rheumatoid arthritis and psoriatic arthritis
US9272035B2 (en) 2011-04-28 2016-03-01 Celgene Corporation Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
EP3034496A1 (en) 2014-12-18 2016-06-22 LEK Pharmaceuticals d.d. Novel solvates of n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1h-isoindol-4-yl]acetamide
US9387195B2 (en) 2011-03-07 2016-07-12 Celgene Corporation Methods for treating diseases using isoindoline compounds
WO2016161996A1 (en) 2015-04-09 2016-10-13 Zentiva, K.S. A method of chiral resolution of the key intermediate of the synthesis of apremilast and its use for the preparation of pure apremilast
WO2016169533A1 (en) 2015-04-24 2016-10-27 Zentiva, K.S. A solid form of apremilast and a process for preparing the same
WO2016192694A1 (en) 2015-06-05 2016-12-08 Zentiva, K.S. A process for preparing the key intermediate of apremilast, using enzymatic resolution of the racemic amines
EP3106457A1 (en) 2015-06-15 2016-12-21 LEK Pharmaceuticals d.d. A novel synthetic pathway towards apremilast
WO2017033116A1 (en) 2015-08-26 2017-03-02 Glenmark Pharmaceuticals Limited Process for preparation of apremilast
EP3144393A1 (en) 2015-09-18 2017-03-22 LEK Pharmaceuticals d.d. A synthetic pathway towards apremilast
WO2017059040A1 (en) 2015-09-29 2017-04-06 Pliva Hrvatska D.O.O. Processes for the preparation of apremilast and intermediates thereof
EP3181549A1 (en) 2015-12-17 2017-06-21 Zaklady Farmaceutyczne Polpharma SA Process for the preparation of apremilast
WO2017118447A1 (en) 2016-01-06 2017-07-13 Zentiva, K.S. A preparation method of amorphous apremilast
US9872854B2 (en) 2013-03-14 2018-01-23 Celgene Corporation Methods for the treatment of psoriatic arthritis using apremilast
US10092541B2 (en) 2014-08-15 2018-10-09 Celgene Corporation Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
WO2018184936A1 (en) 2017-04-04 2018-10-11 Quimica Sintetica, S. A. Resolution of racemic beta-aminosulfone compounds
EP2962690B1 (en) 2002-03-20 2019-01-16 Celgene Corporation (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US10370329B2 (en) * 2015-04-27 2019-08-06 Mylan Laboratories Limited Process for the enantiomeric resolution of apremilast intermediates
US10682336B2 (en) 2015-10-21 2020-06-16 Amgen Inc. PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS)
EP3929179A1 (en) 2020-06-22 2021-12-29 Biohorm, S.L. Anti-inflammatory compounds and methods for their manufacture
EP4183389A1 (en) 2021-11-18 2023-05-24 KRKA, d.d., Novo mesto Pharmaceutical composition comprising apremilast

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
CA2379887C (en) * 2002-04-09 2004-01-20 Bernard Charles Sherman Stable tablets comprising simvastatin
IL165258A0 (en) * 2002-05-17 2005-12-18 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
US7842691B2 (en) * 2002-10-15 2010-11-30 Celgene Corporation Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide
WO2004054501A2 (en) * 2002-11-18 2004-07-01 Celgene Corporation Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
AU2003294311B8 (en) * 2002-11-18 2008-06-05 Celgene Corporation Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
JP2006519875A (en) * 2003-03-06 2006-08-31 セルジーン・コーポレーション Selective cytokine inhibitors for treating central nervous system disorders
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
CA2544591A1 (en) * 2003-11-06 2005-05-26 Celgene Corporation Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009928A1 (en) * 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
PL2574341T3 (en) 2004-03-29 2017-09-29 University Of South Florida Effective treatment of tumors and cancer with triciribine phosphate
US20050239867A1 (en) * 2004-04-23 2005-10-27 Zeldis Jerome B Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
EP1956906A4 (en) 2005-11-09 2009-12-30 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
CN1870631B (en) * 2005-11-11 2010-04-14 华为技术有限公司 Gate control method of media gateway
US20080103086A1 (en) * 2006-10-25 2008-05-01 Jeon-Soo Shin Methods for the treatment of diseases associated with the secretion of hmgb1
CA2694987A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Combinations for the treatment of b-cell proliferative disorders
AU2008276451A1 (en) * 2007-07-17 2009-01-22 Zalicus Inc. Treatments of B-cell proliferative disorders
US20090081173A1 (en) * 2007-08-10 2009-03-26 The Board Of Regents Of The University Of Texas System Methods and compositions involving bacteriophage isolates
CA2718412A1 (en) * 2008-03-24 2009-10-01 Celgene Corporation Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
CN102702070A (en) * 2008-03-27 2012-10-03 细胞基因公司 Solid form containing (+)-2-[1-(3-oxethyl-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, composition and application thereof
US8053364B2 (en) * 2008-05-01 2011-11-08 Intermolecular, Inc. Closed-loop sputtering controlled to enhance electrical characteristics in deposited layer
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
JP2012501592A (en) * 2008-09-01 2012-01-19 ミツビシ エレクトリック ビジュアル ソリューションズ アメリカ， インコーポレイテッド System and method for improving television viewing
US20100186234A1 (en) * 2009-01-28 2010-07-29 Yehuda Binder Electric shaver with imaging capability
CN104962512B (en) * 2009-07-21 2022-09-09 Abt控股公司 Use of stem cells for reducing leukocyte extravasation
CN102053449A (en) * 2009-10-28 2011-05-11 中国科学院福建物质结构研究所 Glutamic acid-derived chiral metal-organic nonlinear optical material
CN102053448A (en) * 2009-10-28 2011-05-11 中国科学院福建物质结构研究所 Nitroaniline chiral non-linear optical material
US9532977B2 (en) 2010-12-16 2017-01-03 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2012083153A1 (en) * 2010-12-16 2012-06-21 Nektar Therapeutics Oligomer-containing apremilast moiety compounds
MX354210B (en) 2010-12-16 2018-02-16 Celgene Corp Controlled release oral dosage forms of poorly soluble drugs and uses thereof.
MX2013007959A (en) 2011-01-10 2013-12-06 Celgene Corp Oral dosage forms of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl]-2-methanesulfonyl-ethyl] -3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide.
US9045417B2 (en) 2011-01-14 2015-06-02 Celgene Corporation Isotopologues of isoindole derivatives
AU2012362562B2 (en) 2011-12-27 2017-11-02 Amgen (Europe) GmbH Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
WO2013119607A2 (en) 2012-02-08 2013-08-15 Celgene Corporation Modified release formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
AR090100A1 (en) 2012-02-21 2014-10-22 Celgene Corp PROCESSES FOR THE PREPARATION OF (S) -1- (3-ETOXI-4-METOXIFENIL) -2-METHANOSULPHONILETILAMINE
US8981117B2 (en) 2012-09-14 2015-03-17 Celgene Corporation Processes for the preparation of isoindole compounds and isotopologues thereof
US20150290171A1 (en) * 2012-11-09 2015-10-15 Celgene Corporation Methods for the treatment of bone loss
EP3539539A1 (en) * 2013-06-17 2019-09-18 Celgene Corporation Tablet formulations of (+)-2-[1 -(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
KR101561828B1 (en) 2013-08-23 2015-10-20 주식회사 아미노로직스 - Process for the racemization of -amino acids
JP2014114308A (en) * 2014-01-31 2014-06-26 Celgene Corp Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
CN103864670B (en) * 2014-03-17 2015-08-26 苏州明锐医药科技有限公司 The preparation method of A Pusite
IN2014MU01283A (en) 2014-04-04 2015-10-09 Cadila Healthcare Ltd
WO2015175251A1 (en) 2014-05-12 2015-11-19 Summit Mining International Inc. Brine leaching process for recovering valuable metals from oxide materials
EP3142748B1 (en) 2014-05-15 2019-09-11 Celgene Corporation Use of pde4 inhibitors and combinations thereof for the treatment of cystic fibrosis
CN105294534B (en) * 2014-07-15 2020-04-10 上海优拓医药科技有限公司 Industrialized method for preparing aplidine and intermediate thereof
CN105622380B (en) * 2014-10-29 2020-06-30 南京安源生物医药科技有限公司 Preparation method of apremilast and intermediate thereof
CN105588886B (en) * 2014-11-18 2020-01-31 重庆医药工业研究院有限责任公司 method for determining impurities in apremilast and its preparation by liquid chromatography
CN104529869B (en) * 2014-12-19 2017-06-13 苏州亚宝药物研发有限公司 A kind of preparation method of (S) 2 [1 (methoxyphenyl of 3 ethyoxyl 4) 2 methylsulfonylethyls] diketone isomers of 4 acetylaminoisoindoline 1,3
WO2016135755A1 (en) 2015-02-27 2016-09-01 Mylan Laboratories Limited Amorphous apremilast, premixes thereof, and novel crystalline forms of apremilast
CN104803906A (en) * 2015-03-17 2015-07-29 南京新伟方医药科技有限公司 Compound as well as preparation method and application thereof
EP3271330A1 (en) 2015-03-19 2018-01-24 Cipla Limited Improved process for the preparation of apremilast
CN106146384B (en) * 2015-04-23 2020-09-22 石药集团中奇制药技术（石家庄）有限公司 Preparation method of high-optical-purity aplidine, obtained product and application thereof
CN104945306B (en) * 2015-05-25 2017-07-21 山东铭康医药技术有限公司 The method for preparing optical voidness Apremilast
WO2016189486A1 (en) 2015-05-26 2016-12-01 Lupin Limited An improved process for preparation of apremilast and novel polymorphs thereof
CN105111127B (en) * 2015-08-20 2019-02-19 济南纽华医药科技有限公司 Apremilast is amorphous and preparation method thereof
WO2017033206A2 (en) * 2015-08-27 2017-03-02 Msn Laboratories Private Limited Solid state forms of n-[2-[(1 s)-1 -(3-ethoxy-4-methoxyphenyl)-2-(methyl sulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-l h-isoindol-4-yl]acetamide and process for preparation thereof
US9765026B2 (en) * 2015-08-28 2017-09-19 Scinopharm Taiwan, Ltd. Forms of apremilast and the process of making the same
CN105218428A (en) * 2015-10-20 2016-01-06 南京美嘉宁逸医药研究开发有限公司 A kind of preparation method of Apremilast of high chiral purity
WO2017083348A1 (en) 2015-11-11 2017-05-18 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2017085568A1 (en) 2015-11-19 2017-05-26 Alembic Pharmaceuticals Limited An improved process and novel polymorphic form of apremilast
CN105348172B (en) * 2015-12-04 2017-11-14 新发药业有限公司 (S) preparation method of the preparation of the mesyl ethamine of 1 (ethyoxyl of 4 methoxyl group 3) phenyl 2 and Apremilast
CN105486785A (en) * 2015-12-23 2016-04-13 成都百裕金阁莱药业有限公司 Method for detecting enantiomer impurity in apremilast
US10774041B2 (en) 2016-04-15 2020-09-15 Davuluri Ramamohan Rao Process for the preparation of apremilast
EP3455209A1 (en) 2016-05-12 2019-03-20 Zaklady Farmaceutyczne Polpharma SA Crystalline forms of apremilast
CN109310624A (en) 2016-06-15 2019-02-05 托伦特药物有限公司 The topical composition of Apremilast
US10196355B2 (en) 2016-06-20 2019-02-05 Johnson Matthey Public Limited Company Forms of apremilast
CN106187857B (en) 2016-06-30 2021-04-06 浙江华海药业股份有限公司 Method for preparing apremilast
IT201600083132A1 (en) * 2016-08-05 2018-02-05 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF AN INHIBITOR OF THE PHOSPHODIESTERASE 4
CN110049968A (en) * 2016-11-09 2019-07-23 广东东阳光药业有限公司 Apremilast eutectic and preparation method thereof
EP3339292A1 (en) 2016-12-23 2018-06-27 Zaklady Farmaceutyczne Polpharma SA Cocrystals of apremilast
US20190374508A1 (en) * 2017-01-27 2019-12-12 Sarudbhava Formulations Private Limited Therapeutic topical compositions of apremilast
CN107445875A (en) * 2017-03-22 2017-12-08 陕西科技大学 A kind of chiral separation method for being used to prepare the high-purity intermediate of Apremilast
EP3619195A4 (en) 2017-05-04 2020-12-02 Unichem Laboratories Ltd Novel process to prepare n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulphonyl) ethyl]-1, 3-dioxo-2,3-dihydro-1h-isoindol-4-yl]acetamide
CN111107874A (en) 2017-09-14 2020-05-05 葛兰素史密斯克莱知识产权发展有限公司 Combination therapy for cancer
CN107721902A (en) * 2017-11-08 2018-02-23 中国科学院上海药物研究所 Cocrystallization of Apremilast and niacinamide and its preparation method and application
CN111821299A (en) * 2019-04-16 2020-10-27 天津合美医药科技有限公司 Use of thiophene derivatives for the treatment of immunoglobulin E (IgE) -mediated diseases
CN111821297A (en) * 2019-04-16 2020-10-27 天津合美医药科技有限公司 Use of isoindoline derivatives for the treatment of immunoglobulin E (IgE) -mediated diseases
US11357775B2 (en) * 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
WO2020222773A1 (en) * 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
US11194866B2 (en) * 2019-08-08 2021-12-07 Google Llc Low entropy browsing history for content quasi-personalization
GB2593363A (en) 2019-08-08 2021-09-22 Google Llc Low entropy browsing history for content quasi-personalization
TWI733294B (en) * 2019-12-30 2021-07-11 國立臺灣師範大學 Methods for preparation of apremilast
CN112220785B (en) * 2020-09-22 2021-12-31 北京鑫开元医药科技有限公司 PDE4 inhibitor pharmaceutical composition, preparation method and application thereof
KR20220047105A (en) 2020-10-08 2022-04-15 주식회사 엔비피헬스케어 Pharmaceutical composition containing apremilast
CN115068467A (en) * 2021-03-15 2022-09-20 中国医学科学院药物研究所 Medical application of andrographolide as LTB4 receptor inhibitor
CN114790164B (en) 2021-08-13 2022-12-27 苏州璞正医药有限公司 Substituted isoindoline-1,3-diketone PDE4 inhibitor and pharmaceutical application thereof
WO2023105286A1 (en) 2021-12-06 2023-06-15 My Personal Therapeutics Ltd A combination treatment for cancer
WO2023121670A1 (en) * 2021-12-23 2023-06-29 Amgen Inc. Oral suspension of apremilast

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US366515A (en) 1887-07-12 Stove-pipe
US3031450A (en) 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
US3322755A (en) 1964-03-10 1967-05-30 Boehringer Sohn Ingelheim Basic-substituted 1, 2, 3, 4-tetrahydropyrimido [5, 4-d]-pyrimidines
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
JPS4966691A (en) 1972-10-30 1974-06-27
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3820636A (en) * 1973-08-16 1974-06-28 Deere & Co Self-adjusting control linkage for an external band brake
US4162316A (en) 1975-03-12 1979-07-24 Dainippon Pharmaceutical Co., Ltd. 1-Substituted-4-(1,2-diphenylethyl)piperazine derivatives and compositions containing the same
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4060615A (en) 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
US4001238A (en) 1976-02-18 1977-01-04 Bristol-Myers Company 1,3,4-oxadiazole amides
US4001237A (en) 1976-02-18 1977-01-04 Bristol-Myers Company Oxazole, isoxazole, thiazole and isothiazole amides
US4047404A (en) 1976-11-17 1977-09-13 Tanno Senshoku Kogyo Co., Ltd. Printed fabric washing apparatus
US4101548A (en) 1977-02-22 1978-07-18 Bristol-Myers Company 1,2,3-Thiadiazole amides
US4209623A (en) 1978-06-07 1980-06-24 Bristol-Myers Company Pyrimidine-5-N-(1H-tetrazol-5-yl)-carboxamides
GB2063249A (en) 1979-10-09 1981-06-03 Mitsubishi Yuka Pharma 4-Phenylphthalazine derivatives
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4912205A (en) 1986-03-20 1990-03-27 Daicel Chemical Industries, Ltd. Alkyl-substituted phenylcarbamate derivative of polysaccharide
DE3770095D1 (en) 1986-08-21 1991-06-20 Pfizer CHINAZOLINDIONE AND PYRIDOPYRIMIDINDIONE.
CA1303037C (en) 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
EP0347146B1 (en) 1988-06-16 1993-09-01 Smith Kline & French Laboratories Limited Fused pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
GB8909560D0 (en) 1989-04-26 1989-06-14 Smith Kline French Lab Chemical compounds
GB8923131D0 (en) 1989-10-13 1989-11-29 Smith Kline French Lab Chemical compounds
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5401774A (en) 1991-03-08 1995-03-28 University Of Arizona Method for treating patients with precancerous lesions by administering substituted sulfonyl idenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
PT100905A (en) 1991-09-30 1994-02-28 Eisai Co Ltd BICYCLE HYGIENEOUS HETEROCYCLIC COMPOUNDS CONTAINING BENZENE, CYCLOHEXAN OR PYRIDINE AND PYRIMIDINE, PYRIDINE OR IMIDAZOLE SUBSTITUTES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5354571A (en) 1992-04-27 1994-10-11 Rheon Automatic Machinery Co., Ltd. Method for aligning and bending individual round elongated dough pieces
US5243826A (en) 1992-07-01 1993-09-14 Apd Cryogenics Inc. Method and apparatus for collecting liquid cryogen
JP2657760B2 (en) 1992-07-15 1997-09-24 小野薬品工業株式会社 4-aminoquinazoline derivatives and pharmaceuticals containing them
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9312210D0 (en) 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
WO1995007267A1 (en) 1993-09-10 1995-03-16 Eisai Co., Ltd. Quinazoline compound
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
US5608914A (en) 1994-11-21 1997-03-11 Keesler; Daren Headcover
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5801195A (en) 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
US5703098A (en) 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
DE19501482A1 (en) 1995-01-19 1996-07-25 Bayer Ag 2,9-disubstituted purine-6-ones
DE19501481A1 (en) 1995-01-19 1996-07-25 Bayer Ag 2,8-disubstituted quinazolinones
DE19501480A1 (en) 1995-01-19 1996-07-25 Bayer Ag 9-substituted 2- (2-n-alkoxyphenyl) -purin-6-one
US5614530A (en) 1995-03-10 1997-03-25 Sterling Winthrop Inc. Substituted N-arylmethyl and heterocyclmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines and compositions and methods of use thereof
US5488055A (en) 1995-03-10 1996-01-30 Sanofi Winthrop Inc. Substituted N-cycloalkylmethyl-1H-pyrazolo(3,4-b)quinolin-4 amines and compositions and methods of use thereof
US6069156A (en) 1995-04-10 2000-05-30 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives as cGMP-PDE inhibitors
TW381092B (en) 1995-07-07 2000-02-01 Otsuka Pharma Co Ltd Novel benzimidazole derivatives for use in treating arteriosclerotic diseases
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5728845A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5736537A (en) 1995-09-12 1998-04-07 Estee Lauder, Inc. Dehydroep:androsterone sailcylate useful against skin atrophy
US5658940A (en) 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
DE19540475A1 (en) 1995-10-20 1997-04-24 Schering Ag Chiral methylphenyloxazolidinones
US5710170A (en) 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
GB9526243D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
TR199801249T2 (en) 1995-12-28 1998-10-21 Fujisawa Pharmaceutical Co,Ltd. Benzimidazole trevleri.
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
DE19617864A1 (en) 1996-04-23 1997-10-30 Schering Ag New chiral phenyldihydrofuranones
DE19632423A1 (en) 1996-08-12 1998-02-19 Merck Patent Gmbh Thienopyrimidines
US6127541A (en) 1996-08-30 2000-10-03 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivatives
ATE229527T1 (en) 1996-10-04 2002-12-15 Kyorin Seiyaku Kk PYRAZOLOPYRIDYLPYRAZINONE DERIVATIVES AND A METHOD FOR THE PRODUCTION THEREOF
DE19642451A1 (en) 1996-10-15 1998-04-16 Merck Patent Gmbh Aminothiophene carboxamides
DE19644228A1 (en) 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidines
KR100239800B1 (en) 1996-11-28 2000-03-02 손경식 4,5-diaminopyrimidine derivatives and its preparation
WO1998038168A1 (en) 1997-02-27 1998-09-03 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
PT975347E (en) 1997-02-28 2008-05-23 Nycomed Gmbh Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists
US6035089A (en) * 1997-06-11 2000-03-07 Lockheed Martin Energy Research Corporation Integrated narrowband optical filter based on embedded subwavelength resonant grating structures
EP1035848B1 (en) 1997-07-31 2003-04-23 Celgene Corporation Substituted alkanohydroxamic acids and method of reducing tnf-alpha levels
US6034089A (en) 1997-10-03 2000-03-07 Merck & Co., Inc. Aryl thiophene derivatives as PDE IV inhibitors
US6020339A (en) 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
DE69813895T2 (en) 1997-11-25 2003-11-06 Warner-Lambert Co. Llc, Morris Plains PHENOLSULFONAMIDES AS PDE-IV INHIBITORS AND THEIR THERAPEUTIC USE
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
WO2000050402A1 (en) 1999-02-25 2000-08-31 Merck Frosst Canada & Co. Pde iv inhibiting compounds, compositions and methods of treatment
US6316472B1 (en) 1999-05-13 2001-11-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
SE9904415D0 (en) 1999-12-03 1999-12-03 Astra Ab New process
ATE290002T1 (en) * 1999-12-23 2005-03-15 Icos Corp CYCLIC AMP SPECIFIC PHOSPHODIESTERASE INHIBITORS
AU2700201A (en) 2000-01-31 2001-08-14 Pfizer Products Inc. Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7123975B2 (en) * 2004-07-22 2006-10-17 Taiwan Semiconductor Manufacturing Co., Ltd. Manufacturing management system and method
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US7838577B2 (en) 2007-07-19 2010-11-23 Sekisui Chemical Co., Ltd. Adhesive for electronic component
RU2503672C2 (en) 2008-01-18 2014-01-10 Оксаген Лимитед Compounds having crth2 antagonist activity
MX2010010454A (en) 2008-03-27 2010-12-20 Celgene Corp Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-meth ylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof.
WO2011063102A1 (en) 2009-11-19 2011-05-26 Celgene Corporation Apremilast for the treatment of sarcoidosis
TW201204719A (en) 2010-06-02 2012-02-01 Ab Science Treatment of rheumatoid arthritis with masitinib

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AKAZOME M ET AL: "Asymmetric recognition of 1-arylethylamines by (R)-phenylglycyl-(R)-phenylglycine and its mechanism", TETRAHEDRON: ASYMMETRY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 8, no. 14, 24 July 1997 (1997-07-24), pages 2331 - 2336, XP004085789, ISSN: 0957-4166 *
LUKE G P ET AL: "Synthesis of (S)-5-(1-aminoethyl)-2-(cyclohexylmethoxy)benzamide", TETRAHEDRON: ASYMMETRY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 10, no. 22, 19 November 1999 (1999-11-19), pages 4393 - 4403, XP004186385, ISSN: 0957-4166 *

Cited By (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019030B2 (en) 1996-08-12 2006-03-28 Celgene Corporation Immunotherapeutic agents
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US11040024B2 (en) 2002-03-20 2021-06-22 Amgen Inc. Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US11260046B2 (en) 2002-03-20 2022-03-01 Amgen Inc. (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
EP2962690B1 (en) 2002-03-20 2019-01-16 Celgene Corporation (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US8093283B2 (en) 2002-03-20 2012-01-10 Celgene Corporation Solid forms comprising (+)-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisinoline-1,3-dione, compositions thereof, and uses thereof
US8629173B2 (en) 2002-03-20 2014-01-14 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US9018243B2 (en) 2002-03-20 2015-04-28 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US9433606B2 (en) 2002-03-20 2016-09-06 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
EP2036553A1 (en) * 2002-10-24 2009-03-18 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US7776907B2 (en) 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
EP1569903A2 (en) * 2002-11-06 2005-09-07 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
EP1569903A4 (en) * 2002-11-06 2009-07-29 Celgene Corp Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
WO2004087148A1 (en) * 2003-03-31 2004-10-14 Kyowa Hakko Kogyo Co. Ltd. Remedy and/or preventive for lung diseases
EP1679967A2 (en) * 2003-10-23 2006-07-19 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drus for treatment, modification and management of pain
JP2007524656A (en) * 2003-10-23 2007-08-30 セルジーン・コーポレーション Compositions comprising selective cytokine inhibitors for treating, modifying and managing pain and methods of use thereof
EP1679967A4 (en) * 2003-10-23 2009-07-15 Celgene Corp Methods of using and compositions comprising selective cytokine inhibitory drus for treatment, modification and management of pain
WO2005056009A1 (en) * 2003-12-12 2005-06-23 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for lung disease
EP1744748A2 (en) * 2004-04-14 2007-01-24 Celgene Corporation Method of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myelodysplastic syndromes
JP2007532642A (en) * 2004-04-14 2007-11-15 セルジーン・コーポレーション Use of selective cytokine inhibitors for the treatment and management of myelodysplastic syndromes and compositions containing the same
EP1744748A4 (en) * 2004-04-14 2009-08-12 Celgene Corp Method of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myelodysplastic syndromes
EP1746989A4 (en) * 2004-05-05 2009-07-29 Celgene Corp Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
EP1746989A1 (en) * 2004-05-05 2007-01-31 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
JP2007536221A (en) * 2004-05-05 2007-12-13 セルジーン・コーポレーション Methods of using selective cytokine inhibitors to treat and manage myeloproliferative disorders and compositions containing the same
WO2005108353A3 (en) * 2004-05-06 2006-10-26 Ceptor Corp Compounds for treating neurologic diseases, otologic diseases, or ophthalmologic diseases and methods of use thereof
WO2005108353A2 (en) * 2004-05-06 2005-11-17 Ceptor Corporation Compounds for treating neurologic diseases, otologic diseases, or ophthalmologic diseases and methods of use thereof
WO2005107725A1 (en) * 2004-05-06 2005-11-17 Biolipox Ab Use of ltb4 inhibitors for the treatment of b-cell leukemias and lymphomas
WO2006065814A1 (en) * 2004-12-13 2006-06-22 Celgene Corporation Compositions comprising pde4 modulators and their use for the treatment or prevention of airway inflammation
JP2008544993A (en) * 2005-06-30 2008-12-11 セルジーン・コーポレーション Process for preparing 4-amino-2- (2,6-dioxopiperidin-3-yl) isoindoline-1,3-dione compound
WO2007079182A1 (en) * 2005-12-29 2007-07-12 Celgene Corporation Methods for treating cutaneous lupus using aminoisoindoline compounds
AU2006332677B2 (en) * 2005-12-29 2012-11-29 Celgene Corporation Methods for treating cutaneous lupus using aminoisoindoline compounds
EA013973B1 (en) * 2005-12-29 2010-08-30 Селджин Корпорейшн Methods for treating cutaneous lupus using aminoisoindoline compounds
EP2695616A1 (en) * 2008-03-27 2014-02-12 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
WO2009120167A1 (en) * 2008-03-27 2009-10-01 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
RU2471782C2 (en) * 2008-03-27 2013-01-10 Селджин Корпорейшн Solid forms containing (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulphonylethyl]-4-acetylaminoisoindoline-1, 3-dione, their compositions and use
CN102898349A (en) * 2008-03-27 2013-01-30 细胞基因公司 Solid containing compound, a composition containing the solid and use of the solid
AU2008353468B2 (en) * 2008-03-27 2015-08-06 Amgen (Europe) GmbH Solid forms comprising (+)-2- [1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl] -4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
EP2687213A1 (en) * 2008-03-27 2014-01-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
AU2010213936B2 (en) * 2009-02-10 2014-07-31 Celgene Corporation Methods of using and compositions comprising PDE4 modulators for treatment, prevention and management of tuberculosis
EP2818164A1 (en) 2009-02-10 2014-12-31 Celgene Corporation Methods of using and compositions comprising PDE4-modulators for treatment, prevention and management of tuberculosis
WO2010093588A1 (en) 2009-02-10 2010-08-19 Celgene Corporation Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
AP3437A (en) * 2009-02-10 2015-10-31 Celgene Corp Methods of using and compositions comprising pde4 modulations for treatment, prevention and management of tuberculosis
CN102387798A (en) * 2009-02-10 2012-03-21 细胞基因公司 Methods of using and compositions comprising PDE4 modulators for treatment, prevention and management of tuberculosis
US10611775B2 (en) 2009-05-14 2020-04-07 Tianjin Hemay Pharmaceutical Co., Ltd. Thiophene derivatives
US9630975B2 (en) 2009-05-14 2017-04-25 Tianjin Hemay Bio-Tech Co., Ltd. Thiophene derivatives
US8952178B2 (en) 2009-05-14 2015-02-10 Tianjin Hemay Bio-Tech Co., Ltd. Thiophene derivatives
US10385062B2 (en) 2009-05-14 2019-08-20 Tianjin Hemay Bio-Tech Co., Ltd. Thiophene derivatives
US9616019B2 (en) 2009-11-10 2017-04-11 Celgene Corporation Nanosuspension of a poorly soluble drug via microfluidization process
US20150265534A1 (en) * 2009-11-10 2015-09-24 Celgene Corporation Nanosuspension of a poorly soluble drug via microfluidization process
US20110124702A1 (en) * 2009-11-10 2011-05-26 Chen Ming J Nanosuspension of a Poorly Soluble Drug via Microfluidization Process
WO2011059931A3 (en) * 2009-11-10 2011-07-14 Celgene Corporation Nanosuspension of a poorly soluble drug made by microfluidization process
US9023886B2 (en) * 2009-11-10 2015-05-05 Celgene Corporation Nanosuspension of a poorly soluble drug via microfluidization process
WO2011127019A2 (en) 2010-04-07 2011-10-13 Celgene Corporation Methods for treating respiratory viral infection
WO2011159750A1 (en) 2010-06-15 2011-12-22 Celgene Corporation Biomarkers for the treatment of psoriasis
AU2012205809B2 (en) * 2011-01-10 2015-09-10 Amgen (Europe) GmbH Phenethylsulfone isoindoline derivatives as inhibitors of PDE 4 and/or cytokines
WO2012096884A1 (en) * 2011-01-10 2012-07-19 Celgene Corporation Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
US8853175B2 (en) 2011-01-10 2014-10-07 Celgene Corporation Phenethylsulfone isoindoline derivatives and their use
US9387195B2 (en) 2011-03-07 2016-07-12 Celgene Corporation Methods for treating diseases using isoindoline compounds
US9272035B2 (en) 2011-04-28 2016-03-01 Celgene Corporation Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
US9872854B2 (en) 2013-03-14 2018-01-23 Celgene Corporation Methods for the treatment of psoriatic arthritis using apremilast
WO2015112568A1 (en) 2014-01-24 2015-07-30 Celgene Corporation Methods for the treatment of obesity using apremilast
US9994522B2 (en) 2014-05-11 2018-06-12 Mapi Pharma Ltd. Amorphous form of apremilast
WO2015173792A1 (en) 2014-05-11 2015-11-19 Mapi Pharma Ltd. Amorphous form of apremilast
WO2015175956A1 (en) 2014-05-16 2015-11-19 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
US9944599B2 (en) 2014-05-28 2018-04-17 Lek Pharmaceuticals D.D. Processes for the preparation of beta-aminosulfone compounds
CN106536479B (en) * 2014-05-28 2018-10-19 斯洛文尼亚莱柯制药股份有限公司 The method for being used to prepare beta-amino sulphones
EP2949645A1 (en) 2014-05-28 2015-12-02 LEK Pharmaceuticals d.d. Processes for the preparation of ß-aminosulfone compounds
WO2015181249A1 (en) 2014-05-28 2015-12-03 Lek Pharmaceuticals D.D. PROCESSES FOR THE PREPARATION OF β-AMINOSULFONE COMPOUNDS
WO2015200177A1 (en) 2014-06-23 2015-12-30 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
US10300042B2 (en) 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
WO2016016824A1 (en) 2014-07-29 2016-02-04 Fundacio Hospital Universitari Vall D' Hebron-Institut De Recerca Differential diagnosis and therapy selection for rheumatoid arthritis and psoriatic arthritis
US10092541B2 (en) 2014-08-15 2018-10-09 Celgene Corporation Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
WO2016097156A1 (en) * 2014-12-18 2016-06-23 Lek Pharmaceuticals D.D. Novel solvates of n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1h-isoindol-4-yl]acetamide
EP3034496A1 (en) 2014-12-18 2016-06-22 LEK Pharmaceuticals d.d. Novel solvates of n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1h-isoindol-4-yl]acetamide
WO2016161996A1 (en) 2015-04-09 2016-10-13 Zentiva, K.S. A method of chiral resolution of the key intermediate of the synthesis of apremilast and its use for the preparation of pure apremilast
WO2016169533A1 (en) 2015-04-24 2016-10-27 Zentiva, K.S. A solid form of apremilast and a process for preparing the same
US10370329B2 (en) * 2015-04-27 2019-08-06 Mylan Laboratories Limited Process for the enantiomeric resolution of apremilast intermediates
WO2016192694A1 (en) 2015-06-05 2016-12-08 Zentiva, K.S. A process for preparing the key intermediate of apremilast, using enzymatic resolution of the racemic amines
EP3106457A1 (en) 2015-06-15 2016-12-21 LEK Pharmaceuticals d.d. A novel synthetic pathway towards apremilast
WO2016202806A1 (en) 2015-06-15 2016-12-22 Lek Pharmaceuticals D.D. A novel synthetic pathway towards apremilast
WO2017033116A1 (en) 2015-08-26 2017-03-02 Glenmark Pharmaceuticals Limited Process for preparation of apremilast
EP3341359B1 (en) * 2015-08-26 2022-03-23 Glenmark Life Sciences Limited Process for preparation of apremilast
EP3144393A1 (en) 2015-09-18 2017-03-22 LEK Pharmaceuticals d.d. A synthetic pathway towards apremilast
WO2017059040A1 (en) 2015-09-29 2017-04-06 Pliva Hrvatska D.O.O. Processes for the preparation of apremilast and intermediates thereof
US10682336B2 (en) 2015-10-21 2020-06-16 Amgen Inc. PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS)
EP3181549A1 (en) 2015-12-17 2017-06-21 Zaklady Farmaceutyczne Polpharma SA Process for the preparation of apremilast
WO2017105263A1 (en) 2015-12-17 2017-06-22 Zaklady Farmaceutyczne Polpharma Sa Process for the preparation of a pharmaceutical agent
WO2017118447A1 (en) 2016-01-06 2017-07-13 Zentiva, K.S. A preparation method of amorphous apremilast
WO2018184936A1 (en) 2017-04-04 2018-10-11 Quimica Sintetica, S. A. Resolution of racemic beta-aminosulfone compounds
EP3929179A1 (en) 2020-06-22 2021-12-29 Biohorm, S.L. Anti-inflammatory compounds and methods for their manufacture
WO2021259860A1 (en) 2020-06-22 2021-12-30 Biohorm, S.L. Anti-inflammatory compounds and methods for their manufacture
EP4183389A1 (en) 2021-11-18 2023-05-24 KRKA, d.d., Novo mesto Pharmaceutical composition comprising apremilast
WO2023089101A1 (en) 2021-11-18 2023-05-25 Krka, D.D., Novo Mesto Pharmaceutical composition comprising apremilast

Also Published As

Publication number Publication date
US20100160405A1 (en) 2010-06-24
IL207149A (en) 2013-12-31
JP5936521B2 (en) 2016-06-22
US9724330B2 (en) 2017-08-08
US10092542B2 (en) 2018-10-09
PT1485087E (en) 2009-10-23
DK2223687T3 (en) 2017-08-14
HK1219049A1 (en) 2017-03-24
US7659302B2 (en) 2010-02-09
KR20120024938A (en) 2012-03-14
DK2420490T3 (en) 2016-10-03
AU2003224729B2 (en) 2008-01-03
IL164147A0 (en) 2005-12-18
US20140024695A1 (en) 2014-01-23
EP2295055A2 (en) 2011-03-16
EP2420490B1 (en) 2016-07-20
SI2223688T1 (en) 2019-11-29
US20080207730A1 (en) 2008-08-28
US11040024B2 (en) 2021-06-22
HUE029682T2 (en) 2017-02-28
CA2479666A1 (en) 2003-10-02
KR20130040257A (en) 2013-04-23
KR20130100219A (en) 2013-09-09
US20030187052A1 (en) 2003-10-02
NL300994I1 (en) 2019-06-26
US9283207B2 (en) 2016-03-15
LUC00125I2 (en) 2019-12-24
EP2223688A1 (en) 2010-09-01
SI2223687T1 (en) 2017-10-30
EP2420490A1 (en) 2012-02-22
HUE043539T2 (en) 2019-08-28
ES2608495T3 (en) 2017-04-11
CN100427085C (en) 2008-10-22
US20140371287A1 (en) 2014-12-18
CY2019032I1 (en) 2020-05-29
MXPA04009075A (en) 2005-07-13
US20190000804A1 (en) 2019-01-03
US7358272B2 (en) 2008-04-15
EP1485087A1 (en) 2004-12-15
EP2295055B1 (en) 2017-06-07
KR20110022736A (en) 2011-03-07
DK2223688T3 (en) 2019-08-19
US7659303B2 (en) 2010-02-09
CY2019032I2 (en) 2020-05-29
KR20100040938A (en) 2010-04-21
EP2223687A1 (en) 2010-09-01
DK2962690T3 (en) 2019-04-15
PT2223687T (en) 2017-07-25
US20050267196A1 (en) 2005-12-01
CN1652772A (en) 2005-08-10
HUE045489T2 (en) 2019-12-30
JP2005525386A (en) 2005-08-25
EP2223687B1 (en) 2017-05-17
CA2756798A1 (en) 2003-10-02
EP1485087B1 (en) 2009-08-26
CY1119340T1 (en) 2018-02-14
EP2962690A1 (en) 2016-01-06
US7427638B2 (en) 2008-09-23
US20080242719A1 (en) 2008-10-02
BE2019C008I2 (en) 2022-08-09
DE60328974D1 (en) 2009-10-08
ES2637547T3 (en) 2017-10-13
EP3524242A1 (en) 2019-08-14
KR101383845B1 (en) 2014-04-10
SI2295055T1 (en) 2017-10-30
US20050192336A1 (en) 2005-09-01
ES2637509T3 (en) 2017-10-13
US20080027123A1 (en) 2008-01-31
CN101683334A (en) 2010-03-31
LUC00125I1 (en) 2019-06-18
EP2311453B1 (en) 2017-06-07
CY1121720T1 (en) 2020-05-29
PT2223688T (en) 2019-09-05
DK2295055T3 (en) 2017-09-11
ATE440599T1 (en) 2009-09-15
US10610516B2 (en) 2020-04-07
EP2223688B1 (en) 2019-05-29
EP2074995A1 (en) 2009-07-01
HK1103985A1 (en) 2008-01-04
IL164147A (en) 2010-11-30
MX366328B (en) 2019-07-05
PT2420490T (en) 2016-10-12
SI1485087T1 (en) 2009-12-31
JP2010106033A (en) 2010-05-13
CA2479666C (en) 2012-01-10
ES2742729T3 (en) 2020-02-17
KR100997001B1 (en) 2010-11-25
CY1109380T1 (en) 2014-07-02
US8455536B2 (en) 2013-06-04
US7507759B2 (en) 2009-03-24
NL300994I2 (en) 2019-07-11
AU2003224729A1 (en) 2003-10-08
EP2295055A3 (en) 2011-03-23
ES2331991T3 (en) 2010-01-22
EP2962690B1 (en) 2019-01-16
PT2295055T (en) 2017-08-29
US20170281597A1 (en) 2017-10-05
HUS1900032I1 (en) 2019-07-29
PT2962690T (en) 2019-04-30
DK1485087T3 (en) 2009-11-02
AU2003224729C1 (en) 2023-04-27
KR101104991B1 (en) 2012-01-16
HK1073426A1 (en) 2005-10-07
US20200306226A1 (en) 2020-10-01
JP2015013893A (en) 2015-01-22
SI2962690T1 (en) 2019-05-31
CY1121888T1 (en) 2020-10-14
CY1119204T1 (en) 2018-02-14
FR19C1046I2 (en) 2022-07-08
ES2717517T3 (en) 2019-06-21
US20160151331A1 (en) 2016-06-02
ES2635361T3 (en) 2017-10-03
FR19C1046I1 (en) 2019-08-09
HUE034348T2 (en) 2018-02-28
KR101263786B1 (en) 2013-05-13
US11260046B2 (en) 2022-03-01
EP2311453A1 (en) 2011-04-20
AU2003224729C9 (en) 2023-06-15
US8802717B2 (en) 2014-08-12
ES2595375T3 (en) 2016-12-29
JP2013047262A (en) 2013-03-07
US20210023051A1 (en) 2021-01-28
NZ535798A (en) 2006-04-28
KR20050012722A (en) 2005-02-02
US6962940B2 (en) 2005-11-08
EP2074995B1 (en) 2016-11-02

Similar Documents

Publication Publication Date Title
US11260046B2 (en) (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
ZA200407651B (en) (+)-2-Ä1-(3-ethoxy-4-methoxyphenyl)2-methylsulfonylethylÜ-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2479666

Country of ref document: CA

Ref document number: 2003577877

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 164147

Country of ref document: IL

Ref document number: PA/a/2004/009075

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003224729

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004/07651

Country of ref document: ZA

Ref document number: 200407651

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020047015190

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 535798

Country of ref document: NZ

REEP Request for entry into the european phase

Ref document number: 2003721414

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003721414

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038110938

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003721414

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020047015190

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 535798

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2003224729

Country of ref document: AU

Date of ref document: 20030320

Kind code of ref document: B

WWE Wipo information: entry into national phase

Ref document number: 207149

Country of ref document: IL